European Journal of Cardio-Thoracic Surgery 55 (2019) 91–115
doi:10.1093/ejcts/ezy301 Advance Access publication 9 October 2018

GUIDELINES

Cite this article as: Batchelor TJP, Rasburn NJ, Abdelnour-Berchtold E, Brunelli A, Cerfolio RJ, Gonzalez M *et al*. Guidelines for enhanced recovery after lung surgery: recommendations of the Enhanced Recovery After Surgery (ERAS®) Society and the European Society of Thoracic Surgeons (ESTS). Eur J Cardiothorac Surg 2019;55:91–115.

Guidelines for enhanced recovery after lung surgery: recommendations of the Enhanced Recovery After Surgery (ERAS®) Society and the European Society of Thoracic Surgeons (ESTS)

Timothy J.P. Batchelor[a,*], Neil J. Rasburn[b], Etienne Abdelnour-Berchtold[c], Alessandro Brunelli[d], Robert J. Cerfolio[e], Michel Gonzalez[c], Olle Ljungqvist[f], René H. Petersen[g], Wanda M. Popescu[h], Peter D. Slinger[i] and Babu Naidu[j]

[a] Department of Thoracic Surgery, University Hospitals Bristol NHS Foundation Trust, Bristol, UK
[b] Department of Anaesthesia, University Hospitals Bristol NHS Foundation Trust, Bristol, UK
[c] Division of Thoracic Surgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
[d] Department of Thoracic Surgery, St. James's University Hospital, Leeds, UK
[e] Department of Cardiothoracic Surgery, New York University Langone Health, New York, NY, USA
[f] Department of Surgery, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
[g] Department of Thoracic Surgery, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
[h] Department of Anesthesiology, Yale University School of Medicine, New Haven, CT, USA
[i] Department of Anesthesia, University Health Network – Toronto General Hospital, Toronto, ON, Canada
[j] Department of Thoracic Surgery, Heart of England NHS Foundation Trust, Birmingham, UK

* Corresponding author. Department of Thoracic Surgery, Bristol Royal Infirmary, Upper Maudlin Street, Bristol BS2 8HW, UK. Tel: +44-117-3423132; e-mail: tim.batchelor@uhbristol.nhs.uk (T.J.P. Batchelor).

Received 14 March 2018; received in revised form 29 July 2018; accepted 31 July 2018

Key question

What is the optimal perioperative management for patients undergoing lung surgery?

Key findings

Recommendations were developed for 45 ERAS items, from initial presentation through to postoperative discharge.

Take-home message

The use of a systematic multimodal perioperative care pathway has the potential to improve outcomes after lung surgery.

© The Author(s) 2018. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Downloaded from https://academic.oup.com/ejcts/article/55/1/91/5124324 by Hopital Maisonneuve-Rosemont user on 11 January 2022

Abstract

Enhanced recovery after surgery is well established in specialties such as colorectal surgery. It is achieved through the introduction of multiple evidence-based perioperative measures that aim to diminish postoperative organ dysfunction while facilitating recovery. This review aims to present consensus recommendations for the optimal perioperative management of patients undergoing thoracic surgery (principally lung resection). A systematic review of meta-analyses, randomized controlled trials, large non-randomized studies and reviews was conducted for each protocol element. Smaller prospective and retrospective cohort studies were considered only when higher-level evidence was unavailable. The quality of the evidence base was graded by the authors and used to form consensus recommendations for each topic. Development of these recommendations was endorsed by the Enhanced Recovery after Surgery Society and the European Society for Thoracic Surgery. Recommendations were developed for a total of 45 enhanced recovery items covering topics related to pre-admission, admission, intraoperative care and postoperative care. Most are based on good-quality studies. In some instances, good-quality data were not available, and subsequent recommendations are generic or based on data extrapolated from other specialties. In other cases, no recommendation can currently be made because either equipoise exists or there is a lack of available evidence. Recommendations are based not only on the quality of the evidence but also on the balance between desirable and undesirable effects. Key recommendations include preoperative counselling, nutritional screening, smoking cessation, prehabilitation for high-risk patients, avoidance of fasting, carbohydrate loading, avoidance of preoperative sedatives, venous thromboembolism prophylaxis, prevention of hypothermia, short-acting anaesthetics to facilitate early emergence, regional anaesthesia, nausea and vomiting control, opioid-sparing analgesia, euvolemic fluid management, minimally invasive surgery, early chest drain removal, avoidance of urinary catheters and early mobilization after surgery. These guidelines outline recommendations for the perioperative management of patients undergoing lung surgery based on the best available evidence. As the recommendation grade for most of the elements is strong, the use of a systematic perioperative care pathway has the potential to improve outcomes after surgery.

Keywords: Enhanced recovery after surgery • Perioperative care • Thoracic surgery • Lung surgery

INTRODUCTION

There is continued interest in the development and systematic implementation of evidence-based perioperative care protocols or 'enhanced recovery after surgery' (ERAS®) pathways such as those already produced by the ERAS® Society across a range of surgical specialties [1–10]. In a meta-analysis of 38 studies, ERAS pathways were seen to be effective in reducing hospital length of stay (LOS) and postoperative complication rates [11]. Colorectal cancer surgery accounted for the majority of the studies included in this meta-analysis, and the specialty has been at the forefront of the development of ERAS pathways since their inception [3, 12–15]. The benefits described are achieved by attenuating the homeostatic disturbance and stress response associated with surgery, which is characterized by catabolism and increased oxygen demand, thereby diminishing postoperative organ dysfunction and facilitating recovery [14–16].

An enhanced recovery pathway addresses the entire patient journey from referral to discharge. Multiple small improvements and efficiencies are adopted in an evidence-based manner by a multidisciplinary team. Individual care elements may not necessarily have significant benefits when studied in isolation, but their combination with other elements of the pathway is thought to have a synergistic effect [14]. More recently, overall compliance with ERAS protocols has been shown to be associated with better patient outcomes [17–19]. At the same time, some elements (such as minimally invasive surgery and early mobilization) appear to be more influential than others [17, 19].

Fast-track multimodal protocols have previously been described in thoracic surgery and appeared to result in a reduction in postoperative complications and/or LOS [20–23]. More recently, specific ERAS pathways for thoracic surgery have been published, most of which demonstrating benefits such as reduced opiate usage, minimization of fluid overload, reduced LOS, decreased hospital costs and reduced pulmonary and cardiac complications [19, 24–30]. An initial systematic review of ERAS pathways in elective lung cancer surgery cautioned against the over-interpretation of results, as the included studies were mainly non-randomized and had methodological flaws [31]. A subsequent review and meta-analysis demonstrated that ERAS pathways in lung cancer surgery are associated with reduced complications, a shorter LOS and cost savings [32]. The authors noted significant heterogeneity between protocols and highlighted the need to develop standardized, evidence-based guidelines for thoracic surgery.

Standardized perioperative care helps to ensure that all patients receive optimal treatment. The goal of this article is to critically review existing evidence and make recommendations for elements of perioperative care in lung surgery.

METHODS

Literature search

The authors convened in May 2016 to discuss topics for inclusion. The topic list was based on the ERAS® Society guidelines for colorectal surgery [3] and gynaecological surgery [7]. After the topics were agreed upon, they were allocated among the group according to expertise. The literature search (1966–2017) used Embase and PubMed to search medical subject headings including 'thoracic surgery', 'lung cancer surgery' and all perioperative ERAS items (Table 1). Reference lists of all eligible articles were crosschecked for other relevant studies.

Study selection

Titles and abstracts were screened by individual reviewers to identify potentially relevant articles. Discrepancies in judgement were resolved by the lead (T.B.) and the senior authors (B.N., N.R. and O.L.). Meta-analyses, systematic reviews, randomized controlled studies, non-randomized controlled studies, reviews and case series were considered for each individual topic.

Downloaded from https://academic.oup.com/ejcts/article/55/1/91/5124324 by Hopital Maisonneuve-Rosemont user on 11 January 2022

Table 1: Guidelines for enhanced recovery after lung surgery: recommendations of the ERAS Society and the ESTS

Recommendations	Evidence level	Recommendation grade
Preoperative phase		
Preadmission information, education and counselling		
Patients should routinely receive dedicated preoperative counselling	Low	Strong
Perioperative nutrition		
Patients should be screened preoperatively for nutritional status and weight loss	High	Strong
Oral nutritional supplements should be given to malnourished patients	Moderate	Strong
Immune-enhancing nutrition may have a role in the malnourished patient postoperatively	Low	Weak
Smoking cessation		
Smoking should be stopped at least 4 weeks before surgery	High	Strong
Alcohol dependency management		
Alcohol consumption (in alcohol abusers) should be avoided for at least 4 weeks before surgery	Moderate	Strong
Anaemia management		
Anaemia should be identified, investigated and corrected preoperatively	High	Strong
Pulmonary rehabilitation and prehabilitation		
Prehabilitation should be considered for patients with borderline lung function or exercise capacity	Low	Strong
Admission		
Preoperative fasting and carbohydrate treatment		
Clear fluids should be allowed up until 2 h before the induction of anaesthesia and solids until 6 h before induction of anaesthesia	High	Strong
Oral carbohydrate loading reduces postoperative insulin resistance and should be used routinely	Low	Strong
Preanaesthetic medication		
Routine administration of sedatives to reduce anxiety preoperatively should be avoided	Moderate	Strong
Perioperative phase		
Venous thromboembolism prophylaxis		
Patients undergoing major lung resection should be treated with pharmacological and mechanical VTE prophylaxis	Moderate	Strong
Patients at high risk of VTE may be considered for extended prophylaxis with LMWH for up to 4 weeks	Low	Weak
Antibiotic prophylaxis and skin preparation		
Routine intravenous antibiotics should be administered within 60 min of, but prior to, the skin incision	High	Strong
Hair clipping is recommended if hair removal is required	High	Strong
Chlorhexidine–alcohol is preferred to povidone-iodine solution for skin preparation	High	Strong
Preventing intraoperative hypothermia		
Maintenance of normothermia with convective active warming devices should be used perioperatively	High	Strong
Continuous measurement of core temperature for efficacy and compliance is recommended	High	Strong
Standard anaesthetic protocol		
Lung-protective strategies should be used during one-lung ventilation	Moderate	Strong
A combination of regional and general anaesthetic techniques should be used	Low	Strong
Short-acting volatile or intravenous anaesthetics, or their combination, are equivalent choices	Low	Strong
PONV control		
Non-pharmacological measures to decrease the baseline risk of PONV should be used in all patients	High	Strong
A multimodal pharmacological approach for PONV prophylaxis is indicated in patients at moderate risk or high risk	Moderate	Strong
Regional anaesthesia and pain relief		
Regional anaesthesia is recommended with the aim of reducing postoperative opioid use. Paravertebral blockade provides equivalent analgesia to epidural anaesthesia	High	Strong
A combination of acetaminophen and NSAIDs should be administered regularly to all patients unless contraindications exist	High	Strong
Ketamine should be considered for patients with pre-existing chronic pain	Moderate	Strong
Dexamethasone may be administered to prevent PONV and reduce pain	Low	Strong
Perioperative fluid management		
Very restrictive or liberal fluid regimes should be avoided in favour of euvolemia	Moderate	Strong
Balanced crystalloids are the intravenous fluid of choice and are preferred to 0.9% saline	High	Strong
Intravenous fluids should be discontinued as soon as possible and replaced with oral fluids and diet	Moderate	Strong
Atrial fibrillation prevention		
Patients taking β-blockers preoperatively should continue to take them in the postoperative period	High	Strong
Magnesium supplementation may be considered in magnesium deplete patients	Low	Weak
It is reasonable to administer diltiazem preoperatively or amiodarone postoperatively for patients at risk	Moderate	Weak
Surgical technique: thoracotomy		
If a thoracotomy is required, a muscle-sparing technique should be performed	Moderate	Strong

Continued

Downloaded from https://academic.oup.com/ejcts/article/doi/10.1093/ejcts/ezx351/5124324 by Hopital Maisonneuve-Rosemont user on 11 January 2022

Table 1: Continued

Recommendations	Evidence level	Recommendation grade
Intercostal muscle- and nerve-sparing techniques are recommended	Moderate	Strong
Reapproximation of the ribs during thoracotomy closure should spare the inferior intercostal nerve	Moderate	Strong
Surgical technique: minimally invasive surgery		
A VATS approach for lung resection is recommended for early-stage lung cancer	High	Strong
Postoperative phase		
Chest drain management		
The routine application of external suction should be avoided	Low	Strong
Digital drainage systems reduce variability in decision-making and should be used	Low	Strong
Chest tubes should be removed even if the daily serous effusion is of high volume (up to 450 ml/24 h)	Moderate	Strong
A single tube should be used instead of 2 after anatomical lung resection	Moderate	Strong
Urinary drainage		
In patients with normal preoperative renal function, a transurethral catheter should not be routinely placed for the sole purpose of monitoring urine output	Moderate	Strong
It is reasonable to place a transurethral catheter in patients with thoracic epidural anaesthesia	Low	Strong
Early mobilization and adjuncts to physiotherapy		
Patients should be mobilized within 24 h of surgery	Low	Strong
Prophylactic minitracheostomy use may be considered in certain high-risk patients	Low	Weak

ERAS: Enhanced Recovery After Surgery; ESTS: European Society of Thoracic Surgeons; LMWH: low-molecular-weight heparin; NSAID: non-steroidal anti-inflammatory drugs; PONV: postoperative nausea and vomiting; VATS: video-assisted thoracoscopic surgery; VTE: venous thromboembolism.

Quality assessment and data analyses

The quality of evidence and recommendations were evaluated according to the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system (see Tables 2 and 3) [33] whereby recommendations are given as follows:

- Strong recommendations indicate that the panel is confident that the desirable effects of adherence to a recommendation outweigh the undesirable effects.
- Weak recommendations indicate that the desirable effects of adherence to a recommendation probably outweigh the undesirable effects, but the panel is less confident.

Recommendations are based not only on the quality of evidence—high, moderate, low and very low—but also on the balance between desirable and undesirable effects. As such, consistent with other ERAS® Guideline Working Groups [3, 7], in some cases strong recommendations may be reached from low-quality data and vice versa. Of note, this would be considered a modified GRADE evaluation since we did not consider resource utilization when making our recommendations [34].

RESULTS

The evidence base, recommendations, evidence level and recommendation grade are provided for each individual ERAS item below.

PREADMISSION INFORMATION, EDUCATION AND COUNSELLING

Preoperative counselling helps to set expectations about surgical and anaesthetic procedures and may diminish fear, fatigue and pain and enhance recovery and early discharge [35]. Verbalized education, leaflets and multimedia information containing explanations of the procedure and cognitive interventions may improve pain control, nausea and anxiety after surgery [36] and general anaesthesia [37]. Patient empowerment through diary keeping also appears to improve postoperative pain control but did not influence LOS in surgical cancer patients in 1 randomized controlled trial (RCT) [38]. Similar results have been demonstrated in patients provided with preoperative video information prior to lung resection [39]. Paradoxically, 1 RCT demonstrated lower levels of postoperative satisfaction following lung resection when patients were given written information [40].

It is uncertain if formal education is superior to informal education [41], but ideally patients should receive information in both written and oral form. The patient and a relative or care provider should meet with all members of the team including the surgeon, anaesthetist and nurse.

Summary and recommendations

Most studies show that counselling provides beneficial effects with no evidence of harm. In particular, pain control appears better following lung resection. It is recommended that patients should routinely receive dedicated preoperative counselling.

Evidence level: Low (conflicting data).

Recommendation grade: Strong.

PERIOPERATIVE NUTRITION

Nutritional components of ERAS include preoperative fluid and carbohydrate loading, avoidance of fasting and early recommencement of oral diet and oral nutritional supplements (ONS) [42]. Carbohydrate loading and early enteral diet are dealt with later in these guidelines.

Malnutrition is an important potentially modifiable risk factor for adverse outcomes after major surgery. In recent thoracic surgical studies, malnutrition and/or weight loss were important risk

Downloaded from https://academic.oup.com/ejcts/article/55/1/91/5124324 by Hopital Maisonneuve-Rosemont user on 11 January 2022

Table 2: GRADE system for rating quality of evidence [33]

Evidence level	Definition
High quality	Further research unlikely to change confidence in estimate of effect
Moderate quality	Further research likely to have important impact on confidence in estimate of effect and may change the estimate
Low quality	Further research very likely to have important impact on confidence in estimate of effect and likely to change the estimate
Very low quality	Any estimate of effect is very uncertain

Table 3: GRADE system for rating strength of recommendations [33]

Recommendation strength	Definition
Strong	When desirable effects of intervention clearly outweigh the undesirable effects or clearly do not
Weak	When trade-offs are less certain, either because of low-quality evidence or because evidence suggests that desirable and undesirable effects are closely balanced

factors for complications after surgery [43–45]. However, it is uncertain whether modifying or optimizing perioperative nutritional state results in a reduction in complications. In rehabilitation programmes for chronic obstructive pulmonary disease (COPD), ONS is recommended and improves patient quality of life and muscle function [46]. Approximately 70% of lung cancer patients have COPD [47]. As lung cancer surgery can be considered a 'fixed exacerbation of COPD', by extrapolation a COPD-type nutrition programme may aid recovery and prevent complications after surgery. In addition, malnutrition and loss of muscle mass are frequent in cancer patients and can have a negative effect on clinical outcomes [48].

Evidence from abdominal surgery suggests that routine pre- and/or postoperative ONS may reduce postoperative weight loss, improve nutritional status and muscle strength and reduce complication rates [49–52]. A recent meta-analysis concluded no benefit of preoperative immune-enhancing nutrition (IEN) in abdominal surgery over standard ONS, although postoperative IEN may improve outcomes [42, 52, 53], particularly in patients with pre-existing malnutrition. It is not clear whether these findings are applicable following thoracic surgery as there is only 1 small study of nutritional supplementation ($n = 58$). Patients were randomized to receive either 10 days of IEN or normal diet preoperatively. There were benefits in terms of a reduced complication rate (although this was mainly due to a difference in air leak) and maintenance of postoperative plasma albumin levels [54].

Routine nutritional screening is useful. Screening tools include the Nutritional Risk Score (NRS), the Malnutrition Universal Screening Tool (MUST) and the Subjective Global Assessment (SGA) tool [42]. ESPEN guidelines recommend delaying surgery to allow for preoperative enteral nutrition in patients with at least one of the following criteria: weight loss >10–15% within 6 months, body mass index (BMI) <18.5 kg/m^2 and serum albumin <30 g/l (with no evidence of hepatic or renal dysfunction) [42]. Current general recommendations suggest administration of 5–7 days of oral supplements before surgery in patients at risk of malnutrition [42].

Summary and recommendations

Patients should be screened preoperatively for nutritional status and weight loss. If deemed at risk, they should be given active nutritional support. ONS can be used to supplement total intake. There is not enough evidence to recommend IEN over ONS preoperatively, but there may be a role in the malnourished patient postoperatively.

Evidence level:
Screening for nutritional status preoperatively: High.
ONS for malnourished patients: Moderate.
IEN: Low (extrapolated).

Recommendation grade:
Screening for nutritional status preoperatively: Strong.
ONS for malnourished patients: Strong.
IEN: Weak (postoperative only).

SMOKING CESSATION

Smoking is associated with a high risk of postoperative complications, but the pulmonary effects of smoking can be improved within 4 weeks of cessation [55]. Early studies indicated that current smokers were twice as likely to experience postoperative pulmonary complications after lung resection surgery than never smokers or those who had not smoked for more than 4 weeks [56]. Paradoxically, recent quitters (i.e. stopped smoking within 4 weeks of surgery) appeared to have an increased incidence of pulmonary complications. Further large studies could not corroborate this paradoxical effect [57, 58]. Rather, while confirming that smoking increased the risks of hospital death and pulmonary complications after lung cancer resection, these risks were mitigated slowly by preoperative cessation. More recently, smoking has not been shown to be a risk factor for pulmonary complications if patients are subjected to intense perioperative physiotherapy regimes [59]. There is also evidence that delaying surgery can result in upstaging and decreased long-term survival in lung cancer patients [60]. Nevertheless, based on the evidence available and accepting that an ideal time period has yet to be clearly defined, a delay of 4 weeks to allow smoking cessation appears reasonable.

Continued smoking at the time of lung cancer surgery is also associated with poor postoperative quality of life and fatigue [61] and reduced long-term survival [62].

While smoking cessation interventions such as behavioural support, pharmacotherapy and nicotine replacement are known to result in short-term smoking cessation and long-term abstinence rates [63, 64], there is weak evidence to show that these smoking cessation measures actively decrease postoperative morbidity. The use of varenicline is associated with an increase in long-term smoking cessation but there is no evidence of a reduction in postoperative morbidity [64, 65]. However, smoking cessation appears to be cost-effective prior to lung surgery [66].

Summary and recommendations

Smoking is associated with an increased risk of postoperative morbidity (especially pulmonary complications) and mortality and ideally should be stopped at least 4 weeks before surgery.

Downloaded from https://academic.oup.com/ejcts/article/doi/10.1093/ejcts/ezac124/6524324 by Hopital Maisonneuve-Rosemont user on 11 January 2022

Evidence level:
Preoperative smoking cessation: High.

Recommendation grade:
Preoperative smoking cessation: Strong.

ALCOHOL DEPENDENCY MANAGEMENT

The effects of alcohol abuse on the liver, pancreas and neurological system are well known. In the perioperative period, the chronic effects of alcohol intake on cardiac function, blood clotting and immune function, in combination with the surgical stress response, contribute to excess morbidity. Alcohol abuse in patients undergoing lung cancer surgery is associated with increased postoperative pulmonary complications and mortality [67–69], and reduced long-term survival [70].

Prior to elective surgery, intensive preoperative interventions aimed at complete alcohol cessation, for at least 4 weeks to reduce postoperative complications, but do not significantly reduce mortality or LOS. However, only a small number of studies are available, and the mechanism by which such interventions reduce complications is unknown. Therefore, the optimal timing of such interventions has yet to be determined [71].

Summary and recommendations
Alcohol is associated with increased perioperative morbidity and mortality and should be avoided for at least 4 weeks before surgery in patients who abuse alcohol.

Evidence level:
Preoperative alcohol cessation: Moderate (small number of studies).

Recommendation grade:
Preoperative alcohol cessation: Strong.

ANAEMIA MANAGEMENT

Preoperative anaemia is associated with postoperative morbidity and mortality [72] and reduced long-term survival [73]. A comprehensive review of blood management has advocated preoperative screening for anaemia [74]. Anaemia should be identified and corrected for iron deficiency and any underlying disorder before elective surgery. Treating anaemia preoperatively helps to avoid adverse effects from anaemia and/or blood transfusion. The risks of surgery are increased with the severity of the anaemia [75]. The speed of response to iron therapy (oral or intravenous) is greater in more severe iron deficiency anaemia. Therefore, prompt identification and treatment is important in reducing the need for erythropoiesis-stimulating agents or blood transfusion. Both erythropoiesis-stimulating agents and perioperative blood transfusion have been associated with poorer outcomes for cancer patients [76, 77]. Long-term cancer survival (including survival in lung cancer patients) is also reduced following perioperative transfusion [76, 78].

Recent guidelines have shown no strong evidence of a benefit from preoperative blood transfusion to improve surgical outcomes (in cardiac surgery patients), and in the absence of other blood management measures, preoperative transfusion does not reduce total transfusion requirements. Where transfusion is considered to be unavoidable, there is no evidence to suggest advantages of pre- over intraoperative transfusion [75]. If possible, the focus should be on preventing further blood loss intraoperatively.

Summary and recommendations
Preoperative anaemia is associated with an increase in postoperative morbidity and mortality and should be identified, investigated and corrected preoperatively. Iron therapy is the preferred first-line treatment for the correction of iron deficiency anaemia. Where possible, blood transfusion or erythropoiesis-stimulating agents should not be used to correct preoperative anaemia.

Evidence level:
Correction of preoperative anaemia: High.

Recommendation grade:
Correction of preoperative anaemia: Strong.

PULMONARY REHABILITATION AND PREHABILITATION

Poorer preoperative exercise capacity is associated with worse long- and short-term clinical outcomes including postoperative complications, LOS [79, 80] and survival [81, 82] following curative lung cancer surgery. Preoperative physical conditioning, or prehabilitation, is the process of enhancing the functional and physiological capacity of an individual to enable them to withstand a stressful event and may aid recovery after surgery [83]. It is the process on the continuum of care that occurs between cancer diagnosis and surgical treatment [84]. In colorectal surgery, prehabilitation is more effective than postoperative rehabilitation in returning a patient to baseline function [85]. Patients with poor physical capacity have the most to gain from preoperative intervention [86].

Several recent systematic reviews and a meta-analysis have concluded that prehabilitation is beneficial, but, because of study heterogeneity, the exact duration, intensity, structure and patient selection to achieve maximum efficacy is uncertain [87–90]. In 21 studies (including 5 RCTs) focusing on pre- rather than postoperative rehabilitation, the intervention was delivered mainly in the outpatient setting or in a training facility [90]. Prescribed exercises included aerobic training (lower and/or upper limbs), with the addition of strength training in some studies. Respiratory exercises were also included in the majority of studies. The addition of other elements, such as relaxation techniques and educational sessions, were inconsistent. The median duration was 4 weeks (range 1–10 weeks) with a frequency of 5 sessions per week (range 2–14 weeks) of moderate to high intensity, generally tailored to the patient's tolerance.

Studies report an improvement in peak oxygen consumption or in functional capacity (measured with the 6-min walk test) from baseline to postintervention [90]. Lung function is also enhanced after prehabilitation compared with baseline.

In addition to improving preoperative fitness, prehabilitation appears to improve postoperative outcomes. Hospital LOS and morbidity were reduced in comparison with standard care in a recent meta-analysis and Cochrane review [87, 90]. Pooled estimates of effect sizes show a significant reduction in both hospital LOS and postoperative pulmonary complications. The effect on pulmonary complications seems to be specific to patients with poor preoperative lung function.

Downloaded from https://academic.oup.com/ejcts/article/55/1/91/5124324 by Hopital Maisonneuve-Rosemont user on 11 January 2022

The small number of studies, and the diversity and validity of tools used, limit assessment of prehabilitation on health-related quality of life.

Summary and recommendations

A preoperative exercise rehabilitation programme can reduce hospital LOS and postoperative pulmonary complications. Because of study heterogeneity, no firm recommendations can be made on the nature of the intervention in terms of exercise modality, delivery, frequency or preoperative duration. Prehabilitation should be considered for patients with borderline lung function or exercise capacity.

Evidence level:

Prehabilitation for patients with borderline lung function or exercise capacity: Low.

Recommendation grade:

Prehabilitation for patients with borderline lung function or exercise capacity: Strong.

PREOPERATIVE FASTING AND CARBOHYDRATE TREATMENT

Evidence has shown that the intake of clear fluids up until 2 h before surgery does not increase gastric content, reduce gastric fluid pH or increase complication rates. Hence, in patients without conditions associated with delayed gastric emptying, the intake of clear fluids up until 2 h before the induction of anaesthesia, as well as limiting fasting for solid food to 6 h before induction, is now recommended [91].

To reduce postoperative insulin resistance and mitigate the associated increased risks for complications, carbohydrate loading before surgery has been advocated to achieve a metabolically fed state. In the last decades, an increasing number of original but small studies, systematic reviews and meta-analyses have shown that carbohydrate loading attenuates the increase in insulin resistance related to surgery and, therefore, should be used routinely in major abdominal surgery [3]. Carbohydrate drinks for preoperative use should be properly tested as not all carbohydrate drinks have the same effects on gastric emptying or insulin action.

Although no studies have been performed in patients undergoing thoracic surgery, these findings are considered valid for lung cancer patients given similarities in patient characteristics. Randomized studies have demonstrated that preoperative carbohydrates improve well-being and reduce nausea and vomiting [92]. No studies have specifically addressed diabetic patients, although limited data indicate that it is likely to be safe in well-controlled diabetics [93].

Summary and recommendations

Patients should be permitted to drink clear fluids up until 2 h before anaesthesia and surgery. Patients should abstain from solids for 6 h prior to induction of anaesthesia. Oral carbohydrate loading reduces postoperative insulin resistance, improves preoperative well-being and should be used routinely. Insufficient data are available for diabetic patients.

Evidence level:

Fasting guidelines for solids and fluids: High.
Carbohydrate loading: Low (extrapolated data).

Recommendation grade:

Fasting guidelines: Strong.
Carbohydrate loading: Strong.

PREANAESTHETIC MEDICATION

In general, thoracic surgical patients are older and present with compromised pulmonary function. The use of short- and long-acting benzodiazepines has been associated with over-sedation, upper airway obstruction, decreased postoperative cognitive function and delirium, especially in older frailer patients [94].

One observational trial found no association between the use of preoperative anxiolytic-sedative agents and a reduction in perceived patient anxiety [95]. A recent randomized control trial showed that the use of long-acting benzodiazepines was associated with an increased time to extubation and a decreased rate of early cognitive recovery. Additionally, premedication with lorazepam did not improve self-reported patient experience on the first postoperative day [96]. Therefore, routine administration of benzodiazepines to decrease preoperative anxiety levels should be avoided. However, small doses of short-acting narcotics may be used during preoperative placement of regional blocks or in extremely anxious patients.

Alternative strategies to reduce perioperative anxiety can be implemented. Patient education regarding perioperative goals and expectations plays an important role in reducing preoperative anxiety [36, 37]. Carbohydrate loading and the avoidance of starvation and dehydration also reduce preoperative discomfort [92]. A Cochrane review identified that melatonin administered 1–2 h before surgery is equally as effective as midazolam in reducing preoperative anxiety in adults [97]. Non-pharmacological measures, such as relaxation techniques and music interventions, may offer a substitute to standard anxiolytic medications [98].

Summary and recommendations

Routine administration of sedatives to reduce anxiety preoperatively should be avoided to hasten postoperative recovery. Alternative non-pharmacological methods to relieve preoperative anxiety should be considered in patients with severe anxiety.

Evidence level:

Avoidance of sedatives: Moderate.

Recommendation grade:

Avoidance of sedatives: Strong.

VENOUS THROMBOEMBOLISM PROPHYLAXIS

In thoracic surgery, the postoperative period carries an increased risk of venous thromboembolism (VTE) events due to both the advanced age of patients and the high frequency of this procedure being performed for lung malignancy [99]. When compared to non-cancer patients undergoing comparable surgical procedures [100, 101], the presence of cancer at least doubles the risk of a patient developing deep venous thrombosis. This risk is increased 3-fold for fatal pulmonary embolism. Moreover, postoperative VTE has been found to increase 30-day mortality after cancer surgery from 1.2% to 8.0% [102].

The incidence of postoperative VTE after thoracic surgery has been estimated at between 0.4% and 51% for deep venous

Downloaded from https://academic.oup.com/ejcts/article/doi/10.1093/ejcts/ezx465/5124324 by Hopital Maisonneuve-Rosemont user on 11 January 2022

thrombosis and from less than 1% to 5% for pulmonary embolism, with 2% of pulmonary embolism cases being lethal [103, 104]. Thoracic surgery patients must, therefore, be considered at high risk of postoperative VTE.

Mechanical and pharmacological venous thromboembolism prophylaxis

The evidence for using VTE prophylaxis after thoracic surgery for lung cancer is relatively limited. A recent Cochrane meta-analysis of 7 studies evaluated the use of VTE prophylaxis in thoracic surgery patients versus inactive or active control [103] and could not demonstrate any significant differences between the prophylactic regimen and the control.

The use of VTE prophylaxis is predominantly based on clinical consensus on the estimated risk of VTE and of postoperative bleeding. American College of Chest Physicians and National Institute for Health and Care Excellence (NICE) guidelines recommend that mechanical VTE prophylaxis (antiembolism stockings, intermittent pneumatic compression devices or foot impulse devices) should be started upon admission and continued until the patient has recovered full mobility [105, 106]. Pharmacological VTE prophylaxis with low-molecular-weight heparin, or unfractionated heparin for patients with renal failure, should be added in patients who have a low risk of major bleeding. For patients at high risk of bleeding, mechanical VTE prophylaxis should be used with graduated compression stocking and intermittent pneumatic compression. Once daily administration of low-molecular-weight heparin seems to be as effective as 2 daily half-dose administrations [107]. It is also recommended that epidural catheters should not be inserted or removed within 12 h of heparin administration [108, 109].

Extended pharmacological venous thromboembolism prophylaxis

Patients undergoing thoracic surgery are at risk of developing VTE after discharge [103]. In a retrospective review of 232 lung resections for cancer, the rate of VTE was 5.2% with one-third occurring after leaving hospital [110]. A recent prospective cohort study demonstrated VTE in 12.1% of 157 patients, all of whom underwent a computed tomography pulmonary angiogram and venous US Doppler 1 month postoperatively, regardless of symptoms [111]. The highest incidence of VTE appears within the first month after the surgery [112]. In patients undergoing pneumonectomy for cancer, the peak of incidence of VTE is 6–7 days postsurgery [113, 114]. Furthermore, the presence of VTE negatively impacts on long-term survival [113].

Various studies have reported that the extension of pharmacological prophylaxis up to 1 month after surgery decreases the risk of VTE in major surgery for cancer [115–118]. Despite this, the need for extended VTE prophylaxis in thoracic surgery patients remains unproven and is controversial, with practice varying widely between surgeons, centres and specialties [119]. No prospective, randomized controlled trials in thoracic surgery have been published to examine the potential benefit of extended, out-of-hospital postoperative VTE prophylaxis. However, in 1 study, extended prophylaxis was introduced based on VTE risk assessment using the Caprini model for high-risk thoracic surgery patients. Patients demonstrated an excellent adherence (97.2%) to post-discharge enoxaparin prophylaxis, and the study reported an overall VTE rate of 2.3% with no post-discharge VTE or bleeding events [120].

Currently, there is no evidence to support the use of oral pharmacological VTE prophylaxis.

Summary and recommendations

All patients undergoing major lung resection should be treated with pharmacological and mechanical VTE prophylaxis. Patients at high risk of VTE may be considered for extended prophylaxis with low-molecular-weight heparin lasting up to 4 weeks.

Evidence level:

Mechanical and pharmacological VTE prophylaxis: Moderate (extrapolated).

Extended pharmacological prophylaxis in high-risk patients: Low.

Recommendation grade:

Mechanical and pharmacological VTE prophylaxis: Strong.

Extended pharmacological prophylaxis in high-risk patients: Weak.

ANTIBIOTIC PROPHYLAXIS AND SKIN PREPARATION

In thoracic surgery, postoperative infection (pneumonia, empyema and wound infection) is an important problem [121–123], typically occurring in 7–14% of patients undergoing lung resection [124]. Lung resection without pre-existing infection is classified as a 'clean contaminated' procedure [125]. Airway colonization with bacterial pathogens has been identified as a risk factor for the development of postoperative pulmonary infectious complications [123, 126]. The incidence of bacterial airway contamination of lung cancer surgery patients has been estimated to be between 10% and 83% [127].

Antibiotic prophylaxis

Preoperative administration of prophylactic antibiotics decreases surgical site infection (SSI) after thoracic surgery but does not demonstrate any effect on the rate of postoperative pneumonia or empyema. Extended postoperative antibacterial prophylaxis is not routinely indicated. A single dose of antibiotics before incision is as effective as up to 48 h of postoperative prophylaxis [121, 122, 124, 126, 128]. Intravenous antibiotics should be given no more than 60 min prior to skin incision, usually at the time of anaesthesia induction [129]. In obese patients with a BMI of >35 kg/m^2, the dose of antibiotics should be adapted and increased [130]. Antibiotic doses during prolonged operations or when blood loss exceeds 1500 ml may be repeated according to the half-life of the chosen medication [131].

Infection caused by various organisms frequently identified in skin and respiratory flora (e.g. *Staphylococcus aureus*, coagulase-negative *Staphylococcus*, *Streptococcus pneumoniae* and Gram-negative bacilli) may be adequately prevented by cephalosporins. These are considered to be the standard for prophylaxis in pulmonary surgery due to their broad spectrum, low cost and low allergenic potential [128]. Amoxicillin–clavulanic acid is an alternative choice, and vancomycin or teicoplanin may be used in penicillin- or cephalosporin-allergic patients. Specific local guidelines should be based on the usual pattern of pulmonary flora and the potential development of antibiotic resistance [126, 127].

Downloaded from https://academic.oup.com/ejcts/article/55/1/91/5124324 by Hopital Maisonneuve-Rosemont user on 11 January 2022

Skin preparation

Patients should shower or bathe the night before or the morning of surgery [132]. Using plain soap is just as effective as using chlorhexidine in decreasing SSI [133]. There is no evidence that hair removal reduces SSI, irrespective of the method chosen (shaving, hair clipping or depilatory cream). However, if hair removal is necessary, hair clipping just before surgery is associated with lower rates of SSI than other methods [134].

A 40% reduction in SSI has been reported after the use of chlorhexidine–alcohol for skin cleansing compared to a povidone-iodine solution in various clean contaminated procedures [135]. Therefore, chlorhexidine–alcohol is preferred over povidone-iodine solutions, although care must be taken to avoid fire-based and burn injuries when electrocautery is used [136].

Summary and recommendations

Routine intravenous antibiotic prophylaxis should be administered within 60 min of, but prior to, the skin incision. Routine extended prophylaxis offers no benefits, but additional doses may be given during prolonged procedures according to the half-life of the antibiotic used. Hair clipping is recommended if hair removal is required. Chlorhexidine–alcohol is preferred to povidone-iodine solution for skin preparation.

Evidence level:
Antibiotic prophylaxis: High.
Hair clipping: High.
Chlorhexidine–alcohol skin preparation: High.

Recommendation grade:
Antibiotic prophylaxis: Strong.
Hair clipping: Strong.
Chlorhexidine–alcohol skin preparation: Strong.

PREVENTING INTRAOPERATIVE HYPOTHERMIA

During anaesthesia and major surgery, hypothermia can occur as a result of prolonged exposure to cold operating room temperatures and impairment of the normal thermoregulatory response. Thoracic surgery patients are at high risk of hypothermia (estimated incidence of 35–50%) as the pleural surface of one hemithorax is exposed to dry air during surgery, leading to potentially important evaporative heat loss [137, 138].

Perioperative hypothermia (defined as a body temperature below 36°C) is associated with impaired drug metabolism, increased SSI, cardiovascular morbidity and increased bleeding secondary to impaired haemostasis [139–142]. In addition, postoperative shivering increases oxygen consumption and can worsen pain [143]. Normothermia can be maintained by different approaches: (i) procedures which decrease heat loss through redistribution (vasodilatation and prewarming); (ii) passive warming systems (room temperature and covering exposed body surfaces) and (iii) active warming systems (direct transfer of heat to the patient) [140].

Warming techniques

The most frequently used technique to prevent hypothermia is active body surface warming. Forced air-warming blankets, heating mattresses under the patient or circulating-water garment systems all achieve similar results in terms of clinical outcomes, and no system seems significantly superior to others [140]. However, convective warming systems present several advantages over conductive warming systems: blanket design, air-to-surface warming, no pressure points, single use and suitability for pre-, peri- and postoperative periods [144–146]. SSIs are significantly less common with the use of active warming compared to conventional methods, with an absolute risk reduction of 13% [143].

Before entering the operating room, prewarming patients with a forced air-warming blanket improves core temperature before surgery [147]. In a recent prospective randomized study in thoracic surgery patients, convective prewarming and additional intraoperative warming with an underbody blanket decreased the rate of postoperative hypothermia to 8% compared to 56% with conductive warming using an underbody mattress [148]. Warming intravenous and irrigation fluids to core body temperature or above has been shown to prevent heat loss and subsequent hypothermia [149].

Temperature monitoring

Temperature should be continuously monitored to guide therapy and avoid hyperthermia, which can have deleterious effects on homeostasis and increase the likelihood of a systemic inflammatory response. The most convenient site to measure core temperature during thoracic surgery is the nasopharynx. Active warming should be continued into the postoperative period until the patient's temperature is greater than 36°C.

Summary and recommendations

Monitoring of patients' temperature is mandatory to guide therapy and to avoid hypothermia and hyperthermia. Maintenance of normothermia with convective active warming devices should be used perioperatively.

Evidence level:
The use of active warming devices: High.
Continuous measurement of core temperature for efficacy and compliance: High.

Recommendation grade:
The use of active warming devices: Strong.
Continuous measurement of core temperature for efficacy and compliance: Strong.

STANDARD ANAESTHETIC PROTOCOL

Ventilation

Within the context of an ERAS programme, no single ventilation strategy during thoracic surgery has been favoured over another. However, one-lung anaesthesia with lung-protective strategies may be associated with better outcomes.

Lung isolation. The majority of procedures, whether open thoracotomy or minimally invasive techniques, employ lung isolation and one-lung ventilation to facilitate access into the operative hemithorax. The majority of thoracic procedures are performed with double-lumen tubes [150]. They tend to be more stable during surgery leading to fewer instances of repositioning of the

Downloaded from https://academic.oup.com/ejcts/article/doi/10.1093/ejcts/ezac124/6524324 by Hopital Maisonneuve-Rosemont user on 11 January 2022

airway device and interruption of surgery [151]. However, there is a tendency for more airway injury and an increased incidence of postoperative sore throat [152]. Bronchial blockers are useful in patients with difficult airways when intubation with a large double-lumen tube is problematic. Whether a double-lumen tube or bronchial blocker is used, it is advisable to use fibrotic bronchoscopy to position the device in the airway and avoid accidental lobar obstruction [153, 154]. The use of FiO_2 of 1.0 for ventilation immediately prior to the initiation of one-lung ventilation increases the rate of collapse of the non-ventilated lung and improves surgical access in the operative hemithorax [155].

Management of one-lung ventilation. There are 2 major complications that influence the strategy for one-lung ventilation during thoracic surgery: the risk of hypoxaemia and the possibility of injury to the ventilated lung. Over the past 3 decades, the incidence of hypoxaemia during one-lung anaesthesia has decreased, and the focus has turned towards preventing lung injury [156]. There has been a trend towards using lung-protective ventilation strategies. Decreasing the tidal volumes during one-lung anaesthesia from traditional large volumes of 10 ml/kg ideal body weight to 4–6 ml/kg is considered to be less injurious to the ventilated single lung [157], although outcomes have not been studied in large randomized controlled trials. Retrospective studies suggest that, when used without positive end-expiratory pressure (PEEP), there is no clear clinical decrease in postoperative lung injury with the smaller tidal volumes [158]. There is a trend towards a decreased incidence of hypoxaemia during one-lung ventilation with larger tidal volumes. However, when smaller tidal volumes are used with PEEP, oxygenation is equivalent [159]. The optimal level of PEEP will vary according to individual respiratory mechanics and is usually in the range of 5–10 cmH_2O [160]. An alveolar recruitment manoeuvre strategy at the onset of one-lung ventilation improves oxygenation but can be associated with a transient decrease in systemic blood pressure [161].

Although most concern has focused on preventing injury to the ventilated lung during one-lung anaesthesia, there is evidence of injury to the non-ventilated (collapsed) lung too. Avoiding complete collapse of the non-ventilated lung by the addition of continuous positive airway pressure during surgery has been shown to decrease the local intraoperative inflammatory response [162].

Non-intubated anaesthesia. There are several potential anaesthetic management strategies for thoracic surgery that do not involve intubation of the airway or positive pressure ventilation, including awake-regional anaesthesia and non-intubated general anaesthesia with spontaneous ventilation. Regional anaesthesia includes both thoracic epidural anaesthesia and paravertebral local anaesthesia, usually in combination with intravenous sedation and suppression of the cough reflex. Reported non-intubated thoracic surgical procedures include lobectomy, pneumonectomy, excision of bullae and lung volume reduction [163]. The majority of the reports of non-intubated thoracic surgery have been single-centre observational studies [164]. Most have shown trends towards equivalent or improved outcomes with non-intubated surgery compared to general anaesthesia and a trend towards shorter hospital stays [165]. One randomized controlled trial of 347 patients having a variety of video-assisted thoracoscopic surgery (VATS) procedures showed an overall decrease in postoperative complications and a shorter postoperative LOS in the non-intubated epidural group compared to the general anaesthesia double-lumen tube group, although the hospital stays were still long by fast-track standards (5.8 vs 7.7 days following bullectomy and 9.5 vs 12.7 days following lobectomy) [166]. Currently, although the technique shows potential, the routine use of non-intubated anaesthesia cannot be recommended.

Anaesthetic technique

Anaesthetic management should focus on short-acting agents that permit early extubation. This is best accomplished using a combination of regional and general anaesthetic techniques. Older volatile anaesthetics such as ether or halothane are potent inhibitors of hypoxic pulmonary vasoconstriction and are associated with a high incidence of hypoxaemia during one-lung ventilation. Modern volatile anaesthetics (isoflurane, sevoflurane and desflurane) are weak inhibitors of hypoxic pulmonary vasoconstriction, and when used in doses $\leq$1 minimal alveolar concentration, there is no clinically relevant difference in oxygenation compared to total intravenous anaesthesia (TIVA) [167]. However, there are differences between TIVA and volatile anaesthetics with respect to the local inflammatory response in the lungs. Desflurane has been shown to significantly mitigate the increase in inflammatory markers during surgery in the ventilated lung compared to TIVA with propofol [168]. Similarly, sevoflurane decreases the inflammatory response in the non-ventilated lung [169]. While volatile anaesthetics have been shown to decrease postoperative mortality and respiratory complications in cardiac surgery [170], this has not been shown to be true in thoracic surgery [171]. Dexmedetomidine, another intravenous anaesthetic/analgesic, improves oxygenation and decreases markers of oxidative stress during thoracic surgery but has not been studied in larger outcome trials [172].

Summary and recommendations

A combination of regional and general anaesthetic techniques should be used to permit early emergence from anaesthesia and extubation. Lung isolation can be provided with either a double-lumen tube or a bronchial blocker, and lung-protective ventilation strategies should be used during one-lung anaesthesia. Non-intubated anaesthesia shows potential but cannot currently be recommended for routine use. Short-acting volatile or intravenous anaesthetics, or their combination, are equivalent choices.

Evidence level:
Lung-protective strategies during one-lung ventilation: Moderate.
Non-intubated thoracic surgery: Low.
Combined regional and general anaesthesia: Low.
Short-acting volatile or intravenous anaesthetics or their combination: Low.

Recommendation grade:
Lung-protective strategies during one-lung ventilation: Strong.
Non-intubated thoracic surgery: Not recommended.
Combined regional and general anaesthesia: Strong.
Short-acting volatile or intravenous anaesthetics or their combination: Strong.

POSTOPERATIVE NAUSEA AND VOMITING CONTROL

Postoperative nausea and vomiting (PONV) remains one of the most frequent complications encountered after surgery [3, 173],

Downloaded from https://academic.oup.com/ejcts/article/55/1/91/5124324 by Hopital Maisonneuve-Rosemont user on 11 January 2022

impacting on the quality of early recovery and representing the leading cause of patient dissatisfaction in the immediate postoperative period. The aetiology of PONV is multifactorial. Multiple risk factors have been identified and can be divided into 3 categories: patient related, anaesthetic related and surgery related. Females, non-smokers and patients with a history of PONV or motion sickness are considered to be at highest risk [174]. The use of volatile anaesthetics is the strongest anaesthesia-related predictor [175]. In addition, nitrous oxide and postoperative opioids have been strongly associated with PONV [5]. Longer anaesthetic and surgical time has also been identified as a predictor [176], although thoracic surgery in general is not considered highly emetogenic.

Non-pharmacological control of postoperative nausea and vomiting

To risk stratify patients and develop an appropriate management plan, several scoring systems are available. The easiest to apply in clinical settings is the simplified Apfel score [173], which stratifies the patient as low risk, medium risk or high risk of PONV. The use of a multimodal approach, combining both non-pharmacological and pharmacological measures, tailored to the individual's risk score is advocated [177]. Among non-pharmacological measures, the use of preoperative carbohydrate loading with the avoidance of fasting and dehydration has been associated with a decreased incidence of PONV [178, 179]. In moderate- and high-risk patients, the intraoperative use of TIVA with propofol decreases the risk of PONV [180]. The use of peripheral nerve blocks (intercostal and paravertebral) or neuraxial anaesthesia (epidural and spinal) for the treatment of postoperative pain may reduce the need for postoperative opiates. Similarly, the use of perioperative non-steroidal anti-inflammatory drugs has a known opioid-sparing effect [181]. Electrical stimulation of the P6 acupoint has a significant impact on decreasing the rates of PONV. Acupoint stimulation is considered to be just as effective if performed either preoperatively or postoperatively [182, 183].

Pharmacological control of PONV

Pharmacological measures include administering one or a combination of antiemetic drugs, depending on the risk identified for each patient. There are several classes of recommended antiemetic drugs, all superior to a placebo in reducing PONV: 5-hydroxytryptamine (5-HT_3) receptor antagonists, neurokinin-1 (NK1) receptor antagonists, corticosteroids, phenothiazines and anticholinergics. Other effective classes (butyrophenones and antihistamines) have significant sedative effects and should be avoided, if possible. A single 8-mg preoperative dose of dexamethasone reduces PONV for the first 24 h and reduces further antiemetic needs for up to 72 h following gastrointestinal surgery [184], while high-dose methylprednisolone also reduces nausea for the first 24 h following VATS lobectomy [185]. Corticosteroid administration does raise concerns for potential blood sugar increases and postoperative infection in all patient populations [186], but it has not been associated with a higher incidence of complications following thoracic surgery [185]. The long-term immunosuppressive and oncologic effects of steroid-based antiemetic drugs are not known [3]. Nevertheless, a single dose of steroids appears to be acceptable as an adjunct to first-line therapy.

A common approach to PONV is to administer 1 drug, usually ondansetron, as prophylaxis to all patients. In patients with a moderate or high-risk profile, the most recent guidelines recommend a multimodal approach, utilizing as many non-pharmacological approaches as possible and at least 2 different classes of antiemetic drugs [177]. Treatment of PONV should be performed with a drug from a different class than the one utilized for prophylaxis [177]. Repeating the dose of a medication used for prophylaxis within 6 h of the initial dose does not provide added benefit.

Summary and recommendations

The use of non-pharmacological measures to decrease the baseline risk of PONV should be implemented in all patients undergoing thoracic surgery. A multimodal pharmacological approach for PONV prophylaxis, in combination with other measures to reduce postoperative opiate consumption, is indicated in patients at moderate or high risk.

Evidence level:
The use of non-pharmacological measures: High.
Multimodal pharmacological approach: Moderate.

Recommendation level:
The use of non-pharmacological measures: Strong.
Multimodal pharmacological approach: Strong.

REGIONAL ANAESTHESIA AND PAIN RELIEF

Pain following thoracic surgery is often severe and can be due to retraction, fracture or dislocation of ribs, injury to the intercostal nerves or irritation of the pleura or intercostal bundles by chest tubes. A standardized multimodal analgesic strategy is required to keep the patient comfortable, allow early mobilization and reduce the risk of pulmonary complications.

Inadequate provision of analgesia following thoracotomy or VATS exacerbates a compromised respiratory status. It may lead to respiratory failure secondary to splinting or pneumonia as a result of an ineffective cough and poor clearance of secretions. Pain increases immediate risks to the patient of hypoxaemia, hypercarbia, increased myocardial work, arrhythmias and ischaemia. High-intensity postoperative pain can also facilitate the development of post-thoracotomy pain syndrome. Therefore, an enhanced recovery pathway for thoracic surgery must combine multimodal enteral and parenteral analgesia with regional analgesia or local anaesthetic techniques while attempting to avoid opioids and their side effects. Patient education is also important as well-informed patients may experience less pain [35].

Pre-emptive analgesia

Pre-emptive analgesia aims to decrease acute postoperative pain, even after the analgesic effects of the pre-emptive drugs have worn off, and to inhibit the development of chronic postoperative pain. A systematic review of pre-emptive analgesia for postoperative pain relief found no evidence of benefit for the pre-emptive administration of systemic opioids, non-steroidal anti-inflammatory drugs (NSAIDs) or ketamine and little evidence of benefit with continuous epidural analgesia [187]. A subsequent meta-analysis concluded that pre-emptive thoracic epidural analgesia (TEA) was associated with a reduction in acute pain after thoracotomy but had no effect on the incidence of chronic post-thoracotomy pain [188].

Downloaded from https://academic.oup.com/ejcts/article/doi/10.1093/ejcts/ezx124/4124324 by Hopital Maisonneuve-Rosemont user on 11 January 2022

Intraoperative regional analgesia

Early ERAS protocols defined epidural analgesia as an essential part of the bundle of intraoperative pain management, and it has been the gold standard technique for pain control after major thoracic surgery for some time. The risks associated with the perioperative use of epidural analgesia are becoming clearer and may be greater than previously thought [189]. Adverse effects include urinary retention, hypotension and muscular weakness. Furthermore, an increasing number of patients are taking oral anticoagulation or have renal failure, potentially increasing the risk of epidural-related complications.

Paravertebral analgesia provides a unilateral block of somatic and sympathetic nerves that lie in the paravertebral space and is particularly useful in unilateral thoracic procedures. Several randomized studies have compared outcomes after TEA or paravertebral block. The results suggest that paravertebral blocks are more effective at reducing respiratory complications than TEA and after the first few hours provide equivalent analgesia [190–192]. Percutaneous paravertebral blockade reduces the risks of developing minor complications (PONV, pruritus, hypotension and urinary retention) compared to TEA, with no difference in acute pain, 30-day mortality, major complications (cardiac and respiratory) or length of hospital stay [192, 193].

Intercostal catheters may be as effective as TEA in terms of postoperative pain. They are more cost-effective, require less time, can be placed by the surgeon at the end of the operation and may be associated with fewer complications [194]. Intercostal blocks have demonstrated reduced post-thoracotomy pain when compared to placebo [191] and do not significantly increase operative time [195].

The serratus anterior plane block [196, 197] is a novel technique with potential use in rescue analgesia. Evidence is lacking but there is a possible role in a single-port VATS or when paravertebral blockade is not appropriate (e.g. pleurectomy and decortication). Liposomal bupivacaine also shows promise when delivered as multilevel intercostal injections, potentially providing blockade of intercostal nerves for up to 96 h [198, 199]. Cryoanalgesia is not recommended as it appears to potentiate chronic pain [200, 201].

Postoperative multimodal analgesia

During the postoperative phase, a multimodal analgesic regimen should be employed with the aim of avoiding or minimizing the use of opioids. Opioids are associated with multiple side effects that may impact on a patient's ability to achieve ERAS targets such as PONV control, early mobilization and a quick return to oral diet. The concept of achieving analgesia through the additive or synergistic effects of different types of analgesics is not new and ideally allows the side effects of individual drugs to be minimized while potentiating their positive effects and reducing the use of opioids.

Acetaminophen. Acetaminophen is a vital part of postoperative pain control and can be administered either intravenously or orally [202]. A recent meta-analysis found that after major surgery, adding acetaminophen reduced morphine consumption by 20% but did not decrease the incidence of morphine-related adverse effects [203]. Acetaminophen at clinical doses has few contraindications or side effects. It is considered safe for patients at risk of renal failure [204].

Non-steroidal anti-inflammatory drugs. An NSAID in combination with acetaminophen is more effective than either drug alone [205]. NSAIDs have been used to control post-thoracotomy pain [206] and significantly improve pain control in patients receiving systemic opioids [207, 208]. NSAIDs may also be effective in controlling the ipsilateral post-thoracotomy shoulder tip pain seen in patients receiving TEA [209, 210]. Renal failure is a particular risk of NSAIDs administration in a number of groups including the elderly [211, 212], pre-existing renal failure and hypovolaemic patients. These risk factors are often present in patients scheduled for thoracic surgery. Although there is a theoretical concern that NSAID-mediated reductions in inflammation may reduce the efficacy of a surgically performed pleurodesis [213], this has not been proven in human studies [214].

N-methyl-D-aspartate (NMDA) antagonists. In a double-blinded study of patients who had undergone thoracic surgery, ketamine reduced morphine consumption and improved early postoperative lung function [215]. In another study, adding a low-dose intravenous infusion of ketamine to TEA improved early post-thoracotomy analgesia [216]. The postoperative use of ketamine should be considered for some patients, for example, those on long-term high-dose opioids.

Gabapentin. Given its mechanism of action and effectiveness in neuropathic states, gabapentin's effectiveness in preventing chronic post-surgical pain has been investigated. There is currently no clinical evidence that it reduces chronic post-surgical pain [217]. While gabapentin appears to reduce early postoperative pain scores and opioid use for patients undergoing a variety of surgical procedures [218], there is no evidence that it reduces acute or chronic pain following thoracic surgery [219, 220]. Furthermore, gabapentin does not decrease the ipsilateral shoulder tip pain seen in patients receiving TEA [221]. Therefore, on current evidence, perioperative gabapentin cannot be recommended.

Glucocorticoids. Glucocorticoids (e.g. dexamethasone and methylprednisolone) have many actions including analgesic, antiemetic, antipyretic and anti-inflammatory effects. Dexamethasone produces a dose-dependent opioid-sparing effect [222] in a general surgical setting and has been particularly effective in reducing pain scores with dynamic movement [223, 224]. These effects have been produced with a single dose of dexamethasone in the range of 10–40 mg with few reported serious side effects. Risks of glucocorticoid use include gastric irritation, impaired wound healing, impaired glucose homeostasis and sodium retention. The optimal dose that balances the advantages against these and other risks has yet to be defined. However, 1 recent trial in VATS lobectomy showed that preoperative high-dose methylprednisolone reduces postoperative pain, nausea and fatigue without increasing the risk of complications [185].

Opioids. Opioids, including patient-controlled analgesia, should be kept to a minimum or avoided entirely. If opioids are used, a balance between the beneficial effects (analgesia, enabling passive expiration and prevention of splinting) and the detrimental effects (PONV, constipation, sedation and the suppression of ventilation and coughing and sighing) must be achieved.

Downloaded from https://academic.oup.com/ejcts/article/55/1/91/5124324 by Hopital Maisonneuve-Rosemont user on 11 January 2022

Summary and recommendations

A standardized multimodal approach to pain relief, including good regional anaesthesia, is recommended with the aim of reducing postoperative opioid use. Paravertebral blockade provides equivalent analgesia to TEA with evidence of a better side-effect profile. Acetaminophen and NSAIDs should be administered regularly to all patients unless contraindications exist. Dexamethasone may be administered to prevent PONV and reduce pain. Ketamine should be considered for patients with pre-existing chronic pain on long-term opiates. Gabapentin cannot currently be recommended as an adjunct to conventional analgesia.

Evidence level:
Regional anaesthesia: High.
Combination of acetaminophen and NSAIDs: High.
Ketamine: Moderate.
Dexamethasone: Low.

Recommendation grade:
Regional anaesthesia: Strong.
Combination of acetaminophen and NSAIDs: Strong.
Ketamine: Strong.
Dexamethasone: Strong.

PERIOPERATIVE FLUID MANAGEMENT

Fluid management encompasses the pre-, intra- and postoperative periods [225, 226]. Preoperatively, carbohydrate loading and the avoidance of starvation ensure that patients should not be dehydrated prior to the induction of anaesthesia [42, 49].

In lung resection surgery, fluid management is complex as patients are prone to developing interstitial and alveolar oedema. The effects of existing pulmonary disease, prior chemoradiotherapy, one-lung ventilation, direct lung manipulation by the surgeon and ischaemia–reperfusion phenomena can all damage the glycocalix and the underlying endothelial cells as well as affecting epithelial alveolar cells and surfactant. This may lead to lung injury [227, 228]. In combination with a liberal fluid regime, there is an increased risk of acute respiratory distress syndrome, atelectasis, pneumonia, empyema and death [68, 229–232]. The extent of the lung resection plays an important role, with the highest incidence of acute respiratory distress syndrome seen following extensive resection and pneumonectomy [233].

Traditionally, a volume-restrictive fluid regime of 1–2 ml/kg/h has been recommended as intraoperative and postoperative maintenance, with a perioperative positive fluid balance of <1500 ml (or 20 ml/kg/24 h). The aim is to control the amount of fluid and minimize the hydrostatic pressure in the pulmonary capillaries [234]. The concern with such restrictive fluid management is that it may produce a hypovolaemic state with impaired tissue perfusion, organ dysfunction and acute kidney injury (AKI). A retrospective analysis of 1442 patients undergoing thoracic surgery found a 5.1% incidence of AKI [235]. Subgroup analysis of patients who received less than 3 ml/kg/h showed no relationship with the development of AKI. Subsequent studies have confirmed that restrictive regimes may result in perioperative oliguria but are not associated with an increased risk of postoperative AKI [236, 237]. Similarly, setting a low perioperative urine output target (0.2 ml/kg/h) or treating oliguria with fluid boluses does not appear to affect postoperative renal function [236–238].

Goal-directed therapy (GDT) has been used in multiple specialties to improve surgical outcomes with conflicting results. A recent meta-analysis in major abdominal surgery compared outcomes between intraoperative GDT and conventional fluid therapy [239]. GDT in those patients managed in a traditional care setting was associated with significant reductions in morbidity and hospital LOS. In contrast, if patients were managed within an ERAS setting, there was little difference in outcomes. Monitoring of cardiac output (by pulse contour analysis or Doppler ultrasound), extravascular lung water (by transpulmonary thermodilution) and/or central venous oximetry may prove to be valuable adjuncts in high-risk patients and complex procedures. However, the current evidence for the use of monitoring devices to direct fluid therapy during thoracic surgery is not conclusive [240, 241].

The aim of maintaining intraoperative euvolemia with a dry lung has been discussed repeatedly [234, 242], and its efficacy has been demonstrated in a small RCT [243]. Over-restriction may eventually lead to organ dysfunction, but rates of 2–3 ml/kg/h are not associated with AKI in lung resection patients. Hypoperfusion can be avoided with the use of vasopressors and a limited amount of fluid to counteract the vasodilatory effects of anaesthetic agents and neuraxial blockade [244]. Additional fluid can be given to compensate blood or exudative loss [245]. In line with other ERAS programmes, balanced crystalloid is currently the fluid of choice over 0.9% saline [246]. In the immediate postoperative period, attention should also be paid to fluid balance and the patient's body weight. Enteral fluid should resume as soon as the patient is lucid and able to swallow [42].

Summary and recommendations

Very restrictive or liberal fluid regimes should be avoided in favour of euvoleamia. Intraoperative hypoperfusion can be avoided with the use of vasopressors and a limited amount of fluid. GDT and the use of non-invasive cardiac output monitors do not currently appear to offer benefits to the thoracic surgical patient. Balanced crystalloids are the intravenous fluid of choice and should be discontinued as soon as possible in the postoperative period to be replaced with oral fluids and diet.

Evidence level:
Euvolemic fluid management: Moderate.
Balanced crystalloids: High.
Early enteral route: Moderate (extrapolated).

Recommendation grade:
Euvolemic fluid management: Strong.
Balanced crystalloids: Strong.
Early enteral route: Strong.

ATRIAL FIBRILLATION PREVENTION

New-onset postoperative atrial fibrillation and flutter (POAF) is common after thoracic surgery with an incidence of approximately 12% following lung resection [247, 248]. Risk factors include increasing age, male sex, Caucasian race, hypertension, COPD, heart failure and valvular heart disease [247]. Following lobectomy, a VATS approach may be protective [247, 249, 250] although this is not a consistent finding [251]; however, increasing the extent of operation (e.g. pneumonectomy compared to lobectomy) increases the risk [248]. The development of postoperative complications is associated with doubling of the incidence of POAF [247]. Although POAF occurring in isolation is associated with an

Downloaded from https://academic.oup.com/ejcts/article/doi/10.1093/ejcts/ezac114/6524324 by Hopital Maisonneuve-Rosemont user on 11 January 2022

increased length of hospital stay and an increased risk of readmission, patients with POAF and additional complications do poorly. They are at increased risk of stroke and in-hospital death [247].

Several prevention strategies for the development of POAF have been recommended in the 2014 American Association for Thoracic Surgery (AATS) Guidelines [252]. Patients taking β-blockers prior to surgery are at risk of developing POAF if withdrawn abruptly. Therefore, β-blockers should be continued through into the postoperative period. In those patients who are magnesium deplete (either with low serum magnesium or suspected total body magnesium depletion), intravenous magnesium may be given perioperatively. Digoxin does not prevent the development of POAF and should not be used. In patients deemed at particular risk of developing POAF, it is reasonable to consider perioperative diltiazem (assuming the patient is not taking β-blockers, and cardiac function is normal) or postoperative amiodarone. However, no clinical model has been developed to identify high-risk patients after lung resection, although the $CHADS_2$ score shows promise [253]. Furthermore, there is little evidence that POAF prophylaxis improves outcomes after thoracic surgery.

Summary and recommendations

Patients taking β-blockers preoperatively should continue to take them in the postoperative period to prevent POAF secondary to acute withdrawal. Magnesium supplementation may be considered in magnesium deplete patients. The administration of diltiazem preoperatively or amiodarone postoperatively is reasonable in patients deemed at high risk, although there is little evidence that POAF prophylaxis improves outcomes.

Evidence level:
Avoid β-blocker withdrawal: High.
Replace magnesium: Low.
Diltiazem or amiodarone prophylaxis in high-risk patients: Moderate.

Recommendation grade:
Avoid β-blocker withdrawal: Strong.
Replace magnesium: Weak.
Diltiazem or amiodarone prophylaxis in high-risk patients: Weak.

SURGICAL TECHNIQUE: THORACOTOMY

Post-thoracotomy pain is one of the most common complaints of the thoracic surgical patient, adding significant morbidity, reducing patient satisfaction and increasing healthcare costs. It arises as a result of chest wall trauma, fractured ribs, damaged peripheral nerves, intercostal nerve and muscle damage and central nervous system hyperexcitability. Intercostal nerve injury appears to be the most important factor in its pathogenesis [254]. Although minimally invasive techniques such as VATS and robotic surgery are increasingly popular, the vast majority of pulmonary resections worldwide are still performed via a thoracotomy. The technique of thoracotomy has evolved with time to minimize postoperative pain.

Incision type

The type of incision made for the thoracotomy procedure depends on the type of operation being performed and the access needed as well as surgeon preference and training. The standard different access locations for thoracotomy include the traditional posterolateral approach or an anterior approach (axillary or anterolateral thoracotomy). A muscle-sparing incision (a thoracotomy that does not involve significant division of the latissimus dorsi or serratus anterior muscle fibres) is more often achieved via an anterior approach. Indeed, the anterior approaches were previously considered to be less painful, but, in a systematic review, a muscle-sparing thoracotomy did not result in less pain or preserved pulmonary function [255]. Although muscle strength and range of motion were better preserved by a muscle-sparing approach, this difference had disappeared by 1 month. A more recent meta-analysis, however, has shown that a muscle-sparing approach results in less postoperative pain up to 1 month following a thoracotomy but pulmonary function and perioperative complications are unchanged [256].

Intercostal nerve-sparing techniques

The creation of an intercostal muscle (ICM) flap, in which the muscle is separated from both ribs and then cut distally just under the serratus anterior muscle, reduces postoperative pain compared to traditional thoracotomy techniques [257, 258]. By keeping the ICM out of the surgical retractor, the intercostal bundle is protected from crush injury. An additional benefit is that the ICM can be used for bronchial or oesophageal buttressing when indicated. A non-divided ICM flap, in which the muscle is separated from both ribs and then left to dangle into the incision, is successful in further reducing pain [259].

Rib reapproximation

When closing thoracotomy incisions, techniques that spare compression of the inferior intercostal nerve during rib reapproximation are associated with less postoperative pain than conventional pericostal sutures. The intracostal suture technique involves drilling small holes through the inferior rib for passage of the rib-approximating suture [260]. The no-compression pericostal suture technique involves passage of the rib-approximating suture along the inferior bony surface of the inferior rib, avoiding compression of the associated ICM and bundle [261].

Summary and recommendations

Muscle-sparing thoracotomy incisions may reduce postoperative pain and preserve muscle function and should be performed where possible. ICM- and nerve-sparing techniques are recommended as they reduce post-thoracotomy pain. Avoiding compression of the inferior intercostal nerve when the ribs are reapproximated may further reduce pain.

Evidence level:
Muscle-sparing thoracotomy: Moderate.
ICM flap: Moderate.
Rib reapproximation avoiding nerve compression: Moderate.

Recommendation grade:
Muscle-sparing thoracotomy: Strong.
ICM flap: Strong.
Rib reapproximation avoiding nerve compression: Strong.

SURGICAL TECHNIQUE: MINIMALLY INVASIVE SURGERY

Since the introduction of VATS lobectomy almost 3 decades ago, the technique has undergone significant improvements. When

Downloaded from https://academic.oup.com/ejcts/article/55/1/91/5124324 by Hopital Maisonneuve-Rosemont user on 11 January 2022

compared to thoracotomy, VATS is associated with less pain, better shoulder function, earlier mobilization, shorter LOS, better preservation of pulmonary function and better quality of life [262]. An early, small randomized study demonstrated fewer complications in the VATS group but no difference in pain [263]. More recently, a larger randomized controlled trial of 206 patients undergoing lobectomy compared an anterolateral thoracotomy to a VATS approach. VATS patients had significantly less pain postoperatively and up to 52 weeks after surgery, improved quality of life and a shorter LOS, but no reduction in complications [264]. A large propensity-matched study from the European Society of Thoracic Surgeons database consisting of 28 771 patients showed a significant reduction in total postoperative complications, major cardiopulmonary complications, atelectasis requiring bronchoscopy, initial ventilation >48 h and wound infection in favour of VATS [251]. This study confirmed the findings of a previous large propensity-matched comparison from the Society of Thoracic Surgeons database [249] and a recent meta-analysis of propensity-matched patients [265]. The clinical benefits of a minimally invasive approach are particularly evident in high-risk patients with poor predicted postoperative lung function [266]. These findings form the basis for the recommendation in the most recent lung cancer guidelines of the American College of Chest Physicians that a VATS approach is preferred in the management of patients with stage I non-small-cell lung cancer [267].

No randomized trials have so far been conducted to determine whether a VATS approach impacts on long-term survival. A systematic review and meta-analysis could not demonstrate any significant difference in loco-regional recurrence, but the data suggested a reduced systemic recurrence rate and an improved 5-year mortality rate for VATS [262]. Another randomized study has shown that VATS lobectomy was associated with reduced perioperative changes in acute phase responses. The authors suggest that this finding may have implications for perioperative tumour immune surveillance in lung cancer patients [268]. Compliance with adjuvant chemotherapy seems to be facilitated by VATS surgery and thereby may also affect survival outcome [269].

In recent years, a uniportal approach has been popularized with potential benefits purported to include less pain and discomfort, but so far there has been no robust data to justify this approach over a conventional multiport approach. A recent randomized trial failed to demonstrate any difference between uniportal and multiport VATS lobectomy [270]. Postoperative pain, LOS and complications rates were equivalent. Robotic-assisted lobectomy may have advantages including 7 degrees of movement, 3-dimensional views, tremor filtration, motion scaling and improved ergonomics. Whether this will translate into improvements in clinical outcomes remains to be seen. Studies have demonstrated the feasibility and safety of the robotic approach, and morbidity rates appear equivalent to VATS [271, 272].

Summary and recommendations

A VATS approach for pulmonary resections is recommended for early-stage lung cancer. The benefits are even more marked in patients with poor respiratory reserve. The number of ports used does not appear to affect outcomes, and so, one VATS approach cannot be recommended over another. Data to support the routine use of robotic surgery are lacking.

Evidence level:

VATS lung resection for early-stage lung cancer: High.

Recommendation grade:

VATS lung resection for early-stage lung cancer: Strong.

CHEST DRAIN MANAGEMENT

Management of chest tubes remains a critical aspect in the postoperative course of patients following lung resection, influencing the recovery phase and hospital stay. Although a drain is necessary for the majority of cases, they can cause pain, reduced pulmonary function and immobility, irrespective of the surgical approach [273].

Suction versus no suction

A number of randomized clinical trials have been published comparing external suction via the chest tube versus no suction in the postoperative period. Theoretically, suction promotes pleura-pleural apposition favouring the sealing of air leak and the drainage of large air leaks. However, suction has also been shown to increase the flow through the chest tube proportional to the level of suction applied [274] and to reduce patient mobilization (if wall suction is used). No suction, on the other hand, has been shown to be effective in some circumstances at reducing the duration of air leak, presumably by decreasing the airflow [275, 276]. However, the absence of suction may be ineffective in draining large air leaks and has been associated with increased risk of other complications (particularly pneumonia and arrhythmia) [277].

The question of whether external suction or its absence has a beneficial effect on clinical outcomes has been the subject of several systematic reviews and clinical guidelines [278–281]. Although the evidence is conflicting, there does not appear to be an advantage to the routine application of external suction in terms of shortening the duration of air leak, chest drainage or LOS.

Digital drainage systems

Digital drainage systems have several advantages over a traditional water seal. They are light, compact and have a built-in suction pump, so do not need to be attached to wall suction, should suction be required, favouring early patient mobilization. They are also able to objectively quantify the volume of air leak. The ability to store information and display trends in air leak over time allows more informed decision-making about chest tube removal and reduces interobserver and clinical practice variability [282].

The objective quantification of air leak is probably the most important factor explaining the clinical benefits found in initial randomized clinical trials comparing digital versus traditional devices. Both chest tube duration and length of hospital stay were found to be shorter after lung resection [283, 284].

Modern digital chest drain devices are able to apply regulated suction to maintain the preset intrapleural pressure. A recent multicentre randomized trial [285] showed that their use reduced the duration of chest tube duration by 1.1 days and the length of hospital stay by 1 day after lobectomy. Higher levels of patient satisfaction paralleled the objective clinical benefits. Subsequent

Downloaded from https://academic.oup.com/ejcts/article/doi/10.1093/ejcts/ezac124/6524324 by Hopital Maisonneuve-Rosemont user on 11 January 2022

randomized studies have not found differences in chest tube duration or hospital stay with digital devices [286, 287], but conservative drain removal protocols may have influenced outcomes in 1 study [286].

Pleural fluid drainage

The amount of pleural fluid output observed daily influences the timing of chest tube removal. Traditionally, most surgeons have accepted a cut-off of approximately 200 ml/day as a threshold, below which it is safe to remove a chest tube. However, this value is based more on dogma than on scientific data or physiology.

Pleural fluid turnover is regulated by Starling forces and by the lymphatic drainage system located at the parietal level. The hourly turnover of the pleural fluid is approximately 0.2 ml/kg leading, in physiological conditions, to its complete renewal in approximately 1 h [288]. Lymphatics act as an efficient negative feedback system to regulate pleural fluid dynamics as they can markedly increase flow (20–30-fold) in response to increased filtration, as occurs after thoracic surgery due to postoperative inflammation.

Studies on more aggressive chest drain removal strategies within fast track programmes have been shown to be safe. A non-chylous fluid threshold of 450 ml/day after thoracotomy was associated with only a 0.55% readmission rate for recurrent symptomatic pleural effusion [289]. A higher threshold of 500 ml/day following VATS lobectomy resulted in an incidence of clinically relevant recurrent effusions (needing drainage or aspiration) in only 2.8% of patients [290].

Number of chest tubes

Traditionally, thoracic surgeons have used 2 chest tubes to drain the pleural space after lobectomy. Several randomized trials have demonstrated that the use of a single chest tube after lobectomy is safe and effective with no differences in residual pleural effusion or the need to reinsert a chest tube but is significantly less painful than 2 drains [291–293]. Furthermore, a single drain is associated with a reduced duration of chest drainage and a smaller volume of fluid drained [293]. The practice of using a single chest tube is supported by findings showing that the static and dynamic pain scores decrease by approximately 40% and the lung function increases by 13% after chest tube removal [273], whether surgery is performed via VATS or thoracotomy.

Summary and recommendations

Chest tubes are painful and inhibit respiratory function. Less conservative chest tube management strategies may improve patient outcomes. The routine application of external suction offers no advantages and should be avoided. The use of digital drainage systems is recommended as they remove variability in clinical decision-making and facilitate early mobilization. They may also reduce chest tube duration and hospital stay. Chest tubes can be removed safely even if the daily serous effusion is of high volume (up to 450 ml/24 h). The use of a single chest tube is associated with less pain and reduced chest tube duration without increasing the risk of recurrent effusion. Therefore, a single tube should be used instead of 2 after a routine anatomical lung resection.

Evidence level:
Avoidance of external suction: Low (conflicting data).
Digital drainage systems: Low (conflicting data).
High pleural fluid output accepted for chest tube removal (up to 450 ml/24 h): Moderate.
Single chest tube: Moderate.

Recommendation grade:
Avoidance of external suction: Strong.
Digital drainage systems: Strong.
High pleural fluid output accepted for chest tube removal (up to 450 ml/24 h): Strong.
Single chest tube: Strong.

URINARY DRAINAGE

Bladder drainage is often used during and after thoracic surgery to monitor urine output. However, the clinical value of monitoring intraoperative urine output is questionable. In patients with normal preoperative renal function, intraoperative urine output does not predict subsequent renal function or AKI [294], and targeting oliguria with fluid boluses does not appear to affect postoperative renal function [236, 238]. Similar results have been found after VATS lung resection [237], suggesting that the practice of administering fluid boluses to enhance urine output is unnecessary. Therefore, with the exception of patients with preexisting renal impairment and those in whom fluid balance is crucial (e.g. some patients undergoing pneumonectomy and prolonged complicated surgery), the practice of placing a transurethral catheter for the sole purpose of monitoring perioperative urine output cannot be recommended.

Postoperative urinary retention (POUR) occurs commonly after surgery, but the lack of a consensus definition makes comparisons between studies difficult. POUR is associated with delayed discharge from hospital, an increased risk of urinary tract infection (UTI) and possible long-term bladder dysfunction. The cause is usually multifactorial and may include increasing age, male sex (as a result of anatomy and an increasing incidence of benign prostatic hypertrophy with age), diabetes mellitus, pain and TEA. Although the true incidence following thoracic surgery is not well documented, 1 study of 'minor' thoracic surgery, in which patients underwent a number of procedures without TEA, showed that 11.6% of patients developed POUR [295]. Currently, however, no validated system exists to identify or prophylactically manage high-risk patients.

Paravertebral blockade, in contrast to TEA, is associated with relatively few urinary side effects [192, 296]. As the incidence of POUR in patients with TEA is 26% [297], a transurethral catheter is commonly placed, normally for the duration of epidural analgesia. Prolonged urinary drainage impedes early mobilization and is associated with increasing risk of UTI [298], and so there has been interest in early removal of transurethral catheters. A systematic review of 4 studies of patients undergoing thoracotomy with TEA showed that early removal of a transurethral catheter was possible within the first 24–48 h after surgery [299]. The incidence of POUR following the removal of a transurethral catheter was acceptably low (5.9%), and the incidence of UTIs was reduced. In a recent large RCT, however, POUR occurred in 12.4% of patients who had their transurethral catheter removed within 48 h of thoracic surgery, compared to only 3.2% of patients whose catheter remained until discontinuation of TEA, without any reduction in the incidence of UTIs [300]. Another large prospective study confirmed high rates of POUR following early transurethral catheter removal (26.7% vs 12.4%) [301].

Downloaded from https://academic.oup.com/ejcts/article/55/1/91/5124324 by Hopital Maisonneuve-Rosemont user on 11 January 2022

Summary and recommendations

In patients with normal preoperative renal function, monitoring of perioperative urine output does not affect renal outcomes, and a transurethral catheter is unnecessary for the sole purpose of monitoring urine output. POUR is common, but no validated system exists to identify or prophylactically manage high-risk patients. POUR is associated with TEA, and it is reasonable to insert a transurethral catheter in these patients. A recommendation on the timing of removal cannot be made.

Evidence level:
A transurethral catheter is not required if its sole purpose is monitoring perioperative urine output: Moderate.
Routine urinary drainage with TEA: Low.

Recommendation grade:
A transurethral catheter is not required if its sole purpose is monitoring perioperative urine output: Strong.
Routine urinary drainage with TEA: Strong.

EARLY MOBILIZATION AND ADJUNCTS TO PHYSIOTHERAPY

Early mobilization is an intuitive component of ERAS meant to counteract several complications related to immobilization and decrease the length of hospital stay. In contrast, bed rest is associated with several deleterious consequences, including physical deconditioning, diminished muscle mass, increased pulmonary complications (atelectasis and pneumonia) and increased risk of VTE [302, 303]. Nevertheless, 2 recent systematic reviews could not demonstrate benefits of early mobilization protocols on postoperative outcomes following thoracic surgery due to the poor quality of studies and conflicting results [89, 304]. Conflicting results on quality of life have also been reported [89, 305].

Postoperative immobility is reported as a significant risk factor for ERAS deviation and prolonged LOS following colorectal surgery [306] and is associated with increased morbidity and LOS following lung cancer resection [19]. Chest tubes, urinary catheters, continued intravenous intake of fluids and inadequate pain control are important barriers to early ambulation, underlining the importance of optimal management of these parameters. Therefore, patients should be mobilized to avoid the deleterious effects of bed rest.

Prophylactic minitracheostomy

Repeated suction via a minitracheostomy (MT) can facilitate sputum clearance. Several historical studies have shown some clinical benefits in prophylactic MT use in patients at high risk of sputum retention [307, 308]. Concerns have been raised regarding complications secondary to insertion of MTs [309], and the benefits of prophylactic MT use in high-risk patients has yet to be validated in the era of minimally invasive surgery.

Incentive spirometry

Incentive spirometry (IS) is often used as an adjunct to standard postoperative physiotherapy. However, studies have failed to demonstrate any benefits of perioperative IS in terms of recovery of lung function or reduced risk of postoperative pulmonary complications [310–313]. There may be a role for IS in high-risk patients, but further studies are required.

Non-invasive positive pressure ventilation

Non-invasive positive pressure ventilation has been widely used to prevent atelectasis following lung surgery, but studies to date have failed to demonstrate any significant clinical benefits [314].

Summary and recommendations

Patients should be mobilized within 24 h of surgery. Prophylactic MT use may be considered in certain high-risk patients. Although IS is often used as a low-risk adjunct to physiotherapy, its benefits are unclear. The routine use of postoperative non-invasive positive pressure ventilation cannot be recommended.

Evidence level:
Early mobilization: Low.
Prophylactic MT in high-risk patients: Low.

Recommendation grade:
Early mobilization: Strong (no harm).
Prophylactic MT in high-risk patients: Weak.

DISCUSSION

These guidelines outline recommendations for the perioperative management of patients undergoing thoracic surgery, based on the best available evidence. In some instances, good-quality data were not available. Consequently, some recommendations are generic or based on data extrapolated from other specialties (alcohol abuse management, preoperative anaemia management, carbohydrate treatment, VTE prophylaxis and early enteral feeding). In other cases, no recommendation can currently be made because either equipoise exists or there is a paucity of evidence (volatile versus intravenous anaesthesia, non-intubated anaesthesia, type of VATS approach, robotic surgery and timing of removal of urinary catheters). Recommendations are based not only on the quality of the evidence but also on the balance between desirable and undesirable effects. As such, strong recommendations may be reached from low-quality or conflicting data and vice versa.

The benefits of ERAS pathways are demonstrable in specialties such as colorectal surgery [11, 12], and there is emerging evidence of their efficacy in thoracic surgery [19, 26–28, 30]. It is hoped that these guidelines will help integrate existing knowledge into practice, align perioperative care and encourage future investigations to address existing knowledge gaps. As the recommendation grade for most of the included ERAS elements is strong, the use of a systematic ERAS pathway has the potential to improve outcomes after thoracic surgery.

ACKNOWLEDGEMENTS

The authors thank Yaron Shargall for his advice on VTE prophylaxis and Kyle Cichos for his help with the section on thoracotomy.

Conflict of interest: Tim Batchelor has received speaker fees from Medtronic, Medela and PulmonX. Robert Cerfolio is a

Downloaded from https://academic.oup.com/ejcts/article/doi/10.1093/ejcts/ezac224/6524324 by Hopital Maisonneuve-Rosemont user on 11 January 2022

consultant for Intuitive, C-SATS, Bovie, Ethicon, Medtronic, Community Health Services, Davol/Bard, Myriad Genetics, KCI and Verb Medical. Olle Ljungqvist is a consultant for Nutricia and has received speaker fees from Nutricia, MSD, BBraun and Fresenius-Kabi. He is the current Chairman of the ERAS Society (www.erassociety.org) and he founded, serves on the board of and owns stock in Encare AB. René Petersen has received speaker fees from Medtronic. All other authors declare no conflict of interest.

REFERENCES

[1] Cerantola Y, Valerio M, Persson B, Jichlinski P, Ljungqvist O, Hubner M *et al*. Guidelines for perioperative care after radical cystectomy for bladder cancer: Enhanced Recovery After Surgery (ERAS(®)) society recommendations. Clin Nutr 2013;32:879–87.

[2] Dort JC, Farwell DG, Findlay M, Huber GF, Kerr P, Shea-Budgell MA *et al*. Optimal perioperative care in major head and neck cancer surgery with free flap reconstruction: a consensus review and recommendations from the Enhanced Recovery After Surgery Society. JAMA Otolaryngol Head Neck Surg 2017;143:292–303.

[3] Gustafsson UO, Scott MJ, Schwenk W, Demartines N, Roulin D, Francis N *et al*. Guidelines for perioperative care in elective colonic surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations. Clin Nutr 2012;31:783–800.

[4] Lassen K, Coolsen MM, Slim K, Carli F, de Aguilar-Nascimento JE, Schäfer M *et al*. Guidelines for perioperative care for pancreaticoduodenectomy: Enhanced Recovery After Surgery (ERAS®) Society recommendations. Clin Nutr 2012;31:817–30.

[5] Melloul E, Hübner M, Scott M, Snowden C, Prentis J, Dejong CH *et al*. Guidelines for perioperative care for liver surgery: Enhanced Recovery After Surgery (ERAS) Society recommendations. World J Surg 2016;40:2425–40.

[6] Mortensen K, Nilsson M, Slim K, Schäfer M, Mariette C, Braga M *et al*. Consensus guidelines for enhanced recovery after gastrectomy: Enhanced Recovery After Surgery (ERAS®) Society recommendations. Br J Surg 2014;101:1209–29.

[7] Nelson G, Altman AD, Nick A, Meyer LA, Ramirez PT, Achtari C *et al*. Guidelines for pre- and intra-operative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations–Part I. Gynecol Oncol 2016;140:313–22.

[8] Nygren J, Thacker J, Carli F, Fearon KC, Norderval S, Lobo DN *et al*. Guidelines for perioperative care in elective rectal/pelvic surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations. Clin Nutr 2012;31:801–16.

[9] Temple-Oberle C, Shea-Budgell MA, Tan M, Semple JL, Schrag C, Barreto M *et al*. Consensus Review of Optimal Perioperative Care in Breast Reconstruction: Enhanced Recovery After Surgery (ERAS) Society recommendations. Plast Reconstr Surg 2017;139:1056e–71e.

[10] Thorell A, MacCormick AD, Awad S, Reynolds N, Roulin D, Demartines N *et al*. Guidelines for perioperative care in bariatric surgery: Enhanced Recovery After Surgery (ERAS) Society recommendations. World J Surg 2016;40:2065–83.

[11] Nicholson A, Lowe MC, Parker J, Lewis SR, Alderson P, Smith AF. Systematic review and meta-analysis of enhanced recovery programmes in surgical patients. Br J Surg 2014;101:172–88.

[12] Greco M, Capretti G, Beretta L, Gemma M, Pecorelli N, Braga M. Enhanced recovery program in colorectal surgery: a meta-analysis of randomized controlled trials. World J Surg 2014;38:1531–41.

[13] Kehlet H. Multimodal approach to control postoperative pathophysiology and rehabilitation. Br J Anaesth 1997;78:606–17.

[14] Kehlet H, Wilmore DW. Evidence-based surgical care and the evolution of fast-track surgery. Ann Surg 2008;248:189–98.

[15] Kehlet H. Fast-track surgery-an update on physiological care principles to enhance recovery. Langenbecks Arch Surg 2011;396:585–90.

[16] Desborough JP. The stress response to trauma and surgery. Br J Anaesth 2000;85:109–17.

[17] ERAS Compliance Group. The impact of enhanced recovery protocol compliance on elective colorectal cancer resection: results from an International Registry. Ann Surg 2015;261:1153–9.

[18] Gustafsson UO, Hausel J, Thorell A, Ljungqvist O, Soop M, Nygren J. Adherence to the enhanced recovery after surgery protocol and outcomes after colorectal cancer surgery. Arch Surg 2011;146:571–7.

[19] Rogers LJ, Bleetman D, Messenger DE, Joshi NA, Wood L, Rasburn NJ *et al*. The impact of enhanced recovery after surgery (ERAS) protocol compliance on morbidity from resection for primary lung cancer. J Thorac Cardiovasc Surg 2018;155:1843–52.

[20] Cerfolio RJ, Pickens A, Bass C, Katholi C. Fast-tracking pulmonary resections. J Thorac Cardiovasc Surg 2001;122:318–24.

[21] Das-Neves-Pereira JC, Bagan P, Coimbra-Israel AP, Grimaillof-Junior A, Cesar-Lopez G, Milanez-de-Campos JR *et al*. Fast-track rehabilitation for lung cancer lobectomy: a five-year experience. Eur J Cardiothorac Surg 2009;36:383–91; discussion 391.

[22] Muehling BM, Halter GL, Schelzig H, Meierhenrich R, Steffen P, Sunder-Plassmann L *et al*. Reduction of postoperative pulmonary complications after lung surgery using a fast track clinical pathway. Eur J Cardiothorac Surg 2008;34:174–80.

[23] Salati M, Brunelli A, Xiumè F, Refai M, Pompili C, Sabbatini A. Does fast-tracking increase the readmission rate after pulmonary resection? A case-matched study. Eur J Cardiothorac Surg 2012;41:1083–7; discussion 1087.

[24] Brunelli A, Thomas C, Dinesh P, Lumb A. Enhanced recovery pathway versus standard care in patients undergoing video-assisted thoracoscopic lobectomy. J Thorac Cardiovasc Surg 2017;154:2084–90.

[25] Giménez-Milà M, Klein AA, Martinez G. Design and implementation of an enhanced recovery program in thoracic surgery. J Thorac Dis 2016;8: S37–45.

[26] Khandhar SJ, Schatz CL, Collins DT, Graling PR, Rosner CM, Mahajan AK *et al*. Thoracic enhanced recovery with ambulation after surgery: a 6-year experience. Eur J Cardiothorac Surg 2018;53:1192–8.

[27] Madani A, Fiore JF, Wang Y, Bejjani J, Sivakumaran L, Mata J *et al*. An enhanced recovery pathway reduces duration of stay and complications after open pulmonary lobectomy. Surgery 2015;158:899–908; discussion 908.

[28] Martin LW, Sarosiek BM, Harrison MA, Hedrick T, Isbell JM, Krupnick AS *et al*. Implementing a thoracic enhanced recovery program: lessons learned in the first year. Ann Thorac Surg 2018;105:1597–604.

[29] Scarci M, Solli P, Bedetti B. Enhanced recovery pathway for thoracic surgery in the UK. J Thorac Dis 2016;8:S78–83.

[30] Van Haren RM, Mehran RJ, Correa AM, Antonoff MB, Baker CM, Woodard TC *et al*. Enhanced recovery decreases pulmonary and cardiac complications following thoracotomy for lung cancer. Ann Thorac Surg 2018;106:272–9.

[31] Fiore JF, Bejjani J, Conrad K, Niculiseanu P, Landry T, Lee L *et al*. Systematic review of the influence of enhanced recovery pathways in elective lung resection. J Thorac Cardiovasc Surg 2016;151:708–15.e6.

[32] Li S, Zhou K, Che G, Yang M, Su J, Shen C *et al*. Enhanced recovery programs in lung cancer surgery: systematic review and meta-analysis of randomized controlled trials. Cancer Manag Res 2017;9:657–70.

[33] Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P *et al*. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924–6.

[34] Brunetti M, Shemilt I, Pregno S, Vale L, Oxman AD, Lord J *et al*. GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence. J Clin Epidemiol 2013;66:140–50.

[35] Egbert LD, Battit GE, Welch CE, Bartlett MK. Reduction of postoperative pain by encouragement and instruction of patients. A study of doctor–patient rapport. N Engl J Med 1964;270:825–7.

[36] Ridgeway V, Mathews A. Psychological preparation for surgery: a comparison of methods. Br J Clin Psychol 1982;21:271–80.

[37] Powell R, Scott NW, Manyande A, Bruce J, Vögele C, Byrne-Davis LM *et al*. Psychological preparation and postoperative outcomes for adults undergoing surgery under general anaesthesia. Cochrane Database Syst Rev 2016;5:CD008646.

[38] Schmidt M, Eckardt R, Scholtz K, Neuner B, von Dossow-Hanfstingl V, Sehouli J *et al*. Patient empowerment improved perioperative quality of care in cancer patients aged ≥ 65 years—a randomized controlled trial. PLoS One 2015;10:e0137824.

[39] Crabtree TD, Puri V, Bell JM, Bontumasi N, Patterson GA, Kreisel D *et al*. Outcomes and perception of lung surgery with implementation of a patient video education module: a prospective cohort study. J Am Coll Surg 2012;214:816–21.e2.

[40] Barlési F, Barrau K, Loundou A, Doddoli C, Simeoni MC, Auquier P *et al*. Impact of information on quality of life and satisfaction of non-small cell lung cancer patients: a randomized study of standardized versus individualized information before thoracic surgery. J Thorac Oncol 2008;3: 1146–52.

[41] Gurusamy KS, Vaughan J, Davidson BR. Formal education of patients about to undergo laparoscopic cholecystectomy. Cochrane Database Syst Rev 2014;2:CD009933.

Downloaded from https://academic.oup.com/ejcts/article/55/1/91/5124324 by Hopital Maisonneuve-Rosemont user on 11 January 2022

[42] Weimann A, Braga M, Carli F, Higashiguchi T, Hübner M, Klek S *et al*. ESPEN guideline: clinical nutrition in surgery. Clin Nutr 2017;36:623–50.
[43] Bagan P, Berna P, De Dominicis F, Das Neves Pereira JC, Mordant P, De La Tour B *et al*. Nutritional status and postoperative outcome after pneumonectomy for lung cancer. Ann Thorac Surg 2013;95:392–6.
[44] Nakagawa T, Toyazaki T, Chiba N, Ueda Y, Gotoh M. Prognostic value of body mass index and change in body weight in postoperative outcomes of lung cancer surgery. Interact CardioVasc Thorac Surg 2016;23:560–6.
[45] Thomas PA, Berbis J, Falcoz PE, Le Pimpec-Barthes F, Bernard A, Jougon J *et al*. National perioperative outcomes of pulmonary lobectomy for cancer: the influence of nutritional status. Eur J Cardiothorac Surg 2014; 45:652–9; discussion 659.
[46] Collins PF, Elia M, Stratton RJ. Nutritional support and functional capacity in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respirology 2013;18:616–29.
[47] Loganathan RS, Stover DE, Shi W, Venkatraman E. Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer. Chest 2006;129:1305–12.
[48] Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F *et al*. ESPEN guidelines on nutrition in cancer patients. Clin Nutr 2017; 36:11–48.
[49] Awad S, Varadhan KK, Ljungqvist O, Lobo DN. A meta-analysis of randomised controlled trials on preoperative oral carbohydrate treatment in elective surgery. Clin Nutr 2013;32:34–44.
[50] Bilku DK, Dennison AR, Hall TC, Metcalfe MS, Garcea G. Role of preoperative carbohydrate loading: a systematic review. Ann R Coll Surg Engl 2014;96:15–22.
[51] Burden S, Todd C, Hill J, Lal S. Pre-operative nutrition support in patients undergoing gastrointestinal surgery. Cochrane Database Syst Rev 2012; 11:CD008879.
[52] Crickmer M, Dunne CP, O'Regan A, Coffey JC, Dunne SS. Benefits of post-operative oral protein supplementation in gastrointestinal surgery patients: a systematic review of clinical trials. World J Gastrointest Surg 2016;8:521–32.
[53] Hegazi RA, Hustead DS, Evans DC. Preoperative standard oral nutrition supplements vs immunonutrition: results of a systematic review and meta-analysis. J Am Coll Surg 2014;219:1078–87.
[54] Kaya SO, Akcam TI, Ceylan KC, Samancılar O, Ozturk O, Usluer O. Is preoperative protein-rich nutrition effective on postoperative outcome in non-small cell lung cancer surgery? A prospective randomized study. J Cardiothorac Surg 2016;11:14.
[55] Sørensen LT. Wound healing and infection in surgery: the pathophysiological impact of smoking, smoking cessation, and nicotine replacement therapy: a systematic review. Ann Surg 2012;255:1069–79.
[56] Nakagawa M, Tanaka H, Tsukuma H, Kishi Y. Relationship between the duration of the preoperative smoke-free period and the incidence of postoperative pulmonary complications after pulmonary surgery. Chest 2001;120:705–10.
[57] Barrera R, Shi W, Amar D, Thaler HT, Gabovich N, Bains MS *et al*. Smoking and timing of cessation: impact on pulmonary complications after thoracotomy. Chest 2005;127:1977–83.
[58] Mason DP, Subramanian S, Nowicki ER, Grab JD, Murthy SC, Rice TW *et al*. Impact of smoking cessation before resection of lung cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database study. Ann Thorac Surg 2009;88:362–70; discussion 370.
[59] Rodriguez M, Gómez-Hernandez MT, Novoa N, Jiménez MF, Aranda JL, Varela G. Refraining from smoking shortly before lobectomy has no influence on the risk of pulmonary complications: a case-control study on a matched population. Eur J Cardiothorac Surg 2017;51: 498–503.
[60] Samson P, Patel A, Garrett T, Crabtree T, Kreisel D, Krupnick AS *et al*. Effects of delayed surgical resection on short-term and long-term outcomes in clinical stage I non-small cell lung cancer. Ann Thorac Surg 2015;99:1906–12; discussion 1913.
[61] Balduyck B, Sardari Nia P, Cogen A, Dockx Y, Lauwers P, Hendriks J *et al*. The effect of smoking cessation on quality of life after lung cancer surgery. Eur J Cardiothorac Surg 2011;40:1432–7; discussion 1437.
[62] Parsons A, Daley A, Begh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ 2010;340:b5569.
[63] Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. https://goldcopd.org (8 September 2018, date last accessed).
[64] Thomsen T, Villebro N, Møller AM. Interventions for preoperative smoking cessation. Cochrane Database Syst Rev 2014;3:CD002294.
[65] Wong J, Abrishami A, Yang Y, Zaki A, Friedman Z, Selby P *et al*. A perioperative smoking cessation intervention with varenicline: a double-blind, randomized, placebo-controlled trial. Anesthesiology 2012;117: 755–64.
[66] Slatore CG, Au DH, Hollingworth W. Cost-effectiveness of a smoking cessation program implemented at the time of surgery for lung cancer. J Thorac Oncol 2009;4:499–504.
[67] Bernard A, Rivera C, Pages PB, Falcoz PE, Vicaut E, Dahan M. Risk model of in-hospital mortality after pulmonary resection for cancer: a national database of the French Society of Thoracic and Cardiovascular Surgery (Epithor). J Thorac Cardiovasc Surg 2011;141:449–58.
[68] Licker M, de Perrot M, Spiliopoulos A, Robert J, Diaper J, Chevalley C *et al*. Risk factors for acute lung injury after thoracic surgery for lung cancer. Anesth Analg 2003;97:1558–65.
[69] Paull DE, Updyke GM, Davis CA, Adebonojo SA. Complications and long-term survival for alcoholic patients with resectable lung cancer. Am J Surg 2004;188:553–9.
[70] Green A, Hauge J, Iachina M, Jakobsen E. The mortality after surgery in primary lung cancer: results from the Danish Lung Cancer Registry. Eur J Cardiothorac Surg 2016;49:589–94.
[71] Oppedal K, Møller AM, Pedersen B, Tønnesen H. Preoperative alcohol cessation prior to elective surgery. Cochrane Database Syst Rev 2012;7: CD008343.
[72] Jean RA, DeLuzio MR, Kraev AI, Wang G, Boffa DJ, Detterbeck FC *et al*. Analyzing risk factors for morbidity and mortality after lung resection for lung cancer using the NSQIP database. J Am Coll Surg 2016;222: 992–1000.e1.
[73] Berardi R, Brunelli A, Tamburrano T, Verdecchia L, Onofri A, Zuccatosta L *et al*. Perioperative anemia and blood transfusions as prognostic factors in patients undergoing resection for non-small cell lung cancers. Lung Cancer 2005;49:371–6.
[74] NHS Blood Transfusion Committee. Patient Blood Management—An Evidence Based Approach to Patient Care. 2014. https://www.transfusionguidelines.org/uk-transfusion-committees/national-blood-transfusion-committee/patient-blood-management (8 September 2018, date last accessed).
[75] Kotzé A, Harris A, Baker C, Iqbal T, Lavies N, Richards T *et al*. British Committee for Standards in Haematology Guidelines on the identification and management of pre-operative anaemia. Br J Haematol 2015; 171:322–31.
[76] Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev 2006;1: CD005033.
[77] Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O *et al*. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2012;12:CD003407.
[78] Luan H, Ye F, Wu L, Zhou Y, Jiang J. Perioperative blood transfusion adversely affects prognosis after resection of lung cancer: a systematic review and a meta-analysis. BMC Surg 2014;14:34.
[79] Friedel G, Fritz P, Goletz S, Kristen R, Brinkmann F, Dierkesmann R *et al*. Postoperative survival of lung cancer patients: are there predictors beyond TNM. Anticancer Res 2013;33:1609–19.
[80] Licker M, Schnyder JM, Frey JG, Diaper J, Cartier V, Inan C *et al*. Impact of aerobic exercise capacity and procedure-related factors in lung cancer surgery. Eur Respir J 2011;37:1189–98.
[81] Brunelli A, Pompili C, Salati M, Refai M, Berardi R, Mazzanti P *et al*. Preoperative maximum oxygen consumption is associated with prognosis after pulmonary resection in stage I non-small cell lung cancer. Ann Thorac Surg 2014;98:238–42.
[82] Jones LW, Watson D, Herndon JE, Eves ND, Haithcock BE, Loewen G *et al*. Peak oxygen consumption and long-term all-cause mortality in non-small cell lung cancer. Cancer 2010;116:4825–32.
[83] Pouwels S, Hageman D, Gommans LN, Willigendael EM, Nienhuijs SW, Scheltinga MR *et al*. Preoperative exercise therapy in surgical care: a scoping review. J Clin Anesth 2016;33:476–90.
[84] Carli F, Silver JK, Feldman LS, McKee A, Gilman S, Gillis C *et al*. Surgical prehabilitation in patients with cancer: State-of-the-Science and recommendations for future research from a panel of subject matter experts. Phys Med Rehabil Clin N Am 2017;28:49–64.
[85] Gillis C, Li C, Lee L, Awasthi R, Augustin B, Gamsa A *et al*. Prehabilitation versus rehabilitation: a randomized control trial in patients undergoing colorectal resection for cancer. Anesthesiology 2014;121:937–47.
[86] Minnella EM, Awasthi R, Gillis C, Fiore JF, Liberman AS, Charlebois P *et al*. Patients with poor baseline walking capacity are most likely to

Downloaded from https://academic.oup.com/ejcts/article/55/1/105/5124324 by Hopital Maisonneuve-Rosemont user on 11 January 2022

improve their functional status with multimodal prehabilitation. Surgery 2016;160:1070–9.
[87] Cavalheri V, Granger C. Preoperative exercise training for patients with non-small cell lung cancer. Cochrane Database Syst Rev 2017;6: CD012020.
[88] Crandall K, Maguire R, Campbell A, Kearney N. Exercise intervention for patients surgically treated for non-small cell lung cancer (NSCLC): a systematic review. Surg Oncol 2014;23:17–30.
[89] Mainini C, Rebelo PF, Bardelli R, Kopliku B, Tenconi S, Costi S *et al*. Perioperative physical exercise interventions for patients undergoing lung cancer surgery: what is the evidence. SAGE Open Med 2016;4: 205031211667385.
[90] Sebio Garcia R, Yáñez Brage MI, Giménez Moolhuyzen E, Granger CL, Denehy L. Functional and postoperative outcomes after preoperative exercise training in patients with lung cancer: a systematic review and meta-analysis. Interact CardioVasc Thorac Surg 2016;23:486–97.
[91] Smith I, Kranke P, Murat I, Smith A, O'Sullivan G, Søreide E *et al*. Perioperative fasting in adults and children: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2011;28: 556–69.
[92] Hausel J, Nygren J, Thorell A, Lagerkranser M, Ljungqvist O. Randomized clinical trial of the effects of oral preoperative carbohydrates on postoperative nausea and vomiting after laparoscopic cholecystectomy. Br J Surg 2005;92:415–21.
[93] Gustafsson UO, Nygren J, Thorell A, Soop M, Hellström PM, Ljungqvist O *et al*. Pre-operative carbohydrate loading may be used in type 2 diabetes patients. Acta Anaesthesiol Scand 2008;52:946–51.
[94] Bilotta F, Lauretta MP, Borozdina A, Mizikov VM, Rosa G. Postoperative delirium: risk factors, diagnosis and perioperative care. Minerva Anestesiol 2013;79:1066–76.
[95] Bucx MJ, Krijtenburg P, Kox M. Preoperative use of anxiolytic-sedative agents; are we on the right track. J Clin Anesth 2016;33:135–40.
[96] Maurice-Szamburski A, Auquier P, Viarre-Oreal V, Cuvillon P, Carles M, Ripart J *et al*. Effect of sedative premedication on patient experience after general anesthesia: a randomized clinical trial. JAMA 2015;313: 916–25.
[97] Hansen MV, Halladin NL, Rosenberg J, Gögenur I, Møller AM. Melatonin for pre- and postoperative anxiety in adults. Cochrane Database Syst Rev 2015;4:CD009861.
[98] Bradt J, Dileo C, Shim M. Music interventions for preoperative anxiety. Cochrane Database Syst Rev 2013;6:CD006908.
[99] Brunelli A. Deep vein thrombosis/pulmonary embolism: prophylaxis, diagnosis, and management. Thorac Surg Clin 2012;22:25–8, v.
[100] Tesselaar ME, Osanto S. Risk of venous thromboembolism in lung cancer. Curr Opin Pulm Med 2007;13:362–7.
[101] White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 2003;90:446–55.
[102] Merkow RP, Bilimoria KY, McCarter MD, Cohen ME, Barnett CC, Raval MV. Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis. Ann Surg 2011;254:131–7.
[103] Christensen TD, Vad H, Pedersen S, Hvas AM, Wotton R, Naidu B. Venous thromboembolism in patients undergoing operations for lung cancer: a systematic review. Ann Thorac Surg 2014;97:394–400.
[104] Di Nisio M, Peinemann F, Porreca E, Rutjes AW. Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery. Cochrane Database Syst Rev 2015;6:CD009658.
[105] Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA *et al*. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e227S–77S.
[106] Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. NICE guideline 89. 2018. https://www.nice.org.uk/guidance/ng89 (8 September 2018, date last accessed).
[107] van Dongen CJ, MacGillavry MR, Prins MH. Once versus twice daily LMWH for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev 2005;3:CD003074.
[108] Bergqvist D, Lindblad B, Mätzsch T. Risk of combining low molecular weight heparin for thromboprophylaxis and epidural or spinal anesthesia. Semin Thromb Hemost 1993;19(Suppl 1):147–51.
[109] Vandermeulen EP, Van Aken H, Vermylen J. Anticoagulants and spinal-epidural anesthesia. Anesth Analg 1994;79:1165–77.
[110] Hachey KJ, Hewes PD, Porter LP, Ridyard DG, Rosenkranz P, McAneny D *et al*. Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer. J Thorac Cardiovasc Surg 2016;151:37–44.e1.
[111] Agzarian J, Hanna WC, Schneider L, Schieman C, Finley CJ, Peysakhovich Y *et al*. Postdischarge venous thromboembolic complications following pulmonary oncologic resection: an underdetected problem. J Thorac Cardiovasc Surg 2016;151:992–9.
[112] Yang Y, Zhou Z, Niu XM, Li ZM, Chen ZW, Jian H *et al*. Clinical analysis of postoperative venous thromboembolism risk factors in lung cancer patients. J Surg Oncol 2012;106:736–41.
[113] Raja S, Idrees JJ, Blackstone EH, He J, Badjatiya A, Mazzone P *et al*. Routine venous thromboembolism screening after pneumonectomy: the more you look, the more you see. J Thorac Cardiovasc Surg 2016;152: 524–32.e2.
[114] Świniarska J, Żekanowska E, Dancewicz M, Bella M, Szczęsny TJ, Kowalewski J. Pneumonectomy due to lung cancer results in a more pronounced activation of coagulation system than lobectomy. Eur J Cardiothorac Surg 2009;36:1064–8.
[115] Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A *et al*. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002;346: 975–80.
[116] Kakkar VV, Balibrea JL, Martínez-González J, Prandoni P, Canbesure SG. Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. J Thromb Haemost 2010;8: 1223–9.
[117] Rasmussen MS, Jorgensen LN, Wille-Jørgensen P, Nielsen JD, Horn A, Mohn AC *et al*. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost 2006;4:2384–90.
[118] Rasmussen MS, Jørgensen LN, Wille-Jørgensen P. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Cochrane Database Syst Rev 2009;1:CD004318.
[119] Agzarian J, Linkins LA, Schneider L, Hanna WC, Finley CJ, Schieman C *et al*. Practice patterns in venous thromboembolism (VTE) prophylaxis in thoracic surgery: a comprehensive Canadian Delphi survey. J Thorac Dis 2017;9:80–7.
[120] Hachey KJ, Sterbling H, Choi DS, Pinjic E, Hewes PD, Munoz J *et al*. Prevention of postoperative venous thromboembolism in thoracic surgical patients: implementation and evaluation of a Caprini risk assessment protocol. J Am Coll Surg 2016;222:1019–27.
[121] Aznar R, Mateu M, Miró JM, Gatell JM, Gimferrer JM, Aznar E *et al*. Antibiotic prophylaxis in non-cardiac thoracic surgery: cefazolin versus placebo. Eur J Cardiothorac Surg 1991;5:515–8.
[122] Bernard A, Pillet M, Goudet P, Viard H. Antibiotic prophylaxis in pulmonary surgery. A prospective randomized double-blind trial of flash cefuroxime versus forty-eight-hour cefuroxime. J Thorac Cardiovasc Surg 1994;107:896–900.
[123] Schussler O, Alifano M, Dermine H, Strano S, Casetta A, Sepulveda S *et al*. Postoperative pneumonia after major lung resection. Am J Respir Crit Care Med 2006;173:1161–9.
[124] Oxman DA, Issa NC, Marty FM, Patel A, Panizales CZ, Johnson NN *et al*. Postoperative antibacterial prophylaxis for the prevention of infectious complications associated with tube thoracostomy in patients undergoing elective general thoracic surgery: a double-blind, placebo-controlled, randomized trial. JAMA Surg 2013;148:440–6.
[125] Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control 1999;27:97–132.
[126] Schussler O, Dermine H, Alifano M, Casetta A, Coignard S, Roche N *et al*. Should we change antibiotic prophylaxis for lung surgery? Postoperative pneumonia is the critical issue. Ann Thorac Surg 2008;86:1727–33.
[127] D'Journo XB, Rolain JM, Doddoli C, Raoult D, Thomas PA. Airways colonizations in patients undergoing lung cancer surgery. Eur J Cardiothorac Surg 2011;40:309–19.
[128] Chang SH, Krupnick AS. Perioperative antibiotics in thoracic surgery. Thorac Surg Clin 2012;22:35–45, vi.
[129] Hawn MT, Richman JS, Vick CC, Deierhoi RJ, Graham LA, Henderson WG *et al*. Timing of surgical antibiotic prophylaxis and the risk of surgical site infection. JAMA Surg 2013;148:649–57.

Downloaded from https://academic.oup.com/ejcts/article/55/1/91/5124324 by Hopital Maisonneuve-Rosemont user on 11 January 2022

[130] Forse RA, Karam B, MacLean LD, Christou NV. Antibiotic prophylaxis for surgery in morbidly obese patients. Surgery 1989;106:750–6; discussion 756.
[131] Swoboda SM, Merz C, Kostuik J, Trentler B, Lipsett PA. Does intraoperative blood loss affect antibiotic serum and tissue concentrations. Arch Surg 1996;131:1165–71; discussion 1171.
[132] Berríos-Torres SI, Umscheid CA, Bratzler DW, Leas B, Stone EC, Kelz RR *et al*. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. JAMA Surg 2017;152: 784–91.
[133] Webster J, Osborne S. Preoperative bathing or showering with skin antiseptics to prevent surgical site infection. Cochrane Database Syst Rev 2015;2:CD004985.
[134] Tanner J, Norrie P, Melen K. Preoperative hair removal to reduce surgical site infection. Cochrane Database Syst Rev 2011;11:CD004122.
[135] Darouiche RO, Wall MJ, Itani KM, Otterson MF, Webb AL, Carrick MM *et al*. Chlorhexidine-alcohol versus povidone-iodine for surgical-site antisepsis. N Engl J Med 2010;362:18–26.
[136] Rocos B, Donaldson LJ. Alcohol skin preparation causes surgical fires. Ann R Coll Surg Engl 2012;94:87–9.
[137] Karalapillai D, Story DA, Calzavacca P, Licari E, Liu YL, Hart GK. Inadvertent hypothermia and mortality in postoperative intensive care patients: retrospective audit of 5050 patients. Anaesthesia 2009;64: 968–72.
[138] Karalapillai D, Story D, Hart GK, Bailey M, Pilcher D, Schneider A *et al*. Postoperative hypothermia and patient outcomes after major elective non-cardiac surgery. Anaesthesia 2013;68:605–11.
[139] Kurz A, Sessler DI, Lenhardt R. Perioperative normothermia to reduce the incidence of surgical-wound infection and shorten hospitalization. Study of Wound Infection and Temperature Group. N Engl J Med 1996; 334:1209–15.
[140] Madrid E, Urrútia G, Roqué I Figuls M, Pardo-Hernandez H, Campos JM, Paniagua P *et al*. Active body surface warming systems for preventing complications caused by inadvertent perioperative hypothermia in adults. Cochrane Database Syst Rev 2016;4:CD009016.
[141] Rajagopalan S, Mascha E, Na J, Sessler DI. The effects of mild perioperative hypothermia on blood loss and transfusion requirement. Anesthesiology 2008;108:71–7.
[142] Sessler DI. Complications and treatment of mild hypothermia. Anesthesiology 2001;95:531–43.
[143] Scott EM, Buckland R. A systematic review of intraoperative warming to prevent postoperative complications. AORN J 2006;83:1090–104; 1107.
[144] Galvão CM, Marck PB, Sawada NO, Clark AM. A systematic review of the effectiveness of cutaneous warming systems to prevent hypothermia. J Clin Nurs 2009;18:627–36.
[145] Nieh HC, Su SF. Meta-analysis: effectiveness of forced-air warming for prevention of perioperative hypothermia in surgical patients. J Adv Nurs 2016;72:2294–314.
[146] Sessler DI. Mild perioperative hypothermia. N Engl J Med 1997;336: 1730–7.
[147] Horn EP, Bein B, Böhm R, Steinfath M, Sahili N, Höcker J. The effect of short time periods of pre-operative warming in the prevention of perioperative hypothermia. Anaesthesia 2012;67:612–17.
[148] Emmert A, Franke R, Brandes IF, Hinterthaner M, Danner BC, Bauer M *et al*. Comparison of conductive and convective warming in patients undergoing video-assisted thoracic surgery: a prospective randomized clinical trial. Thorac Cardiovasc Surg 2017;65:362–6.
[149] Campbell G, Alderson P, Smith AF, Warttig S. Warming of intravenous and irrigation fluids for preventing inadvertent perioperative hypothermia. Cochrane Database Syst Rev 2015;4:CD009891.
[150] Shelley B, Macfie A, Kinsella J. Anesthesia for thoracic surgery: a survey of UK practice. J Cardiothorac Vasc Anesth 2011;25:1014–7.
[151] Narayanaswamy M, McRae K, Slinger P, Dugas G, Kanellakos GW, Roscoe A *et al*. Choosing a lung isolation device for thoracic surgery: a randomized trial of three bronchial blockers versus double-lumen tubes. Anesth Analg 2009;108:1097–101.
[152] Clayton-Smith A, Bennett K, Alston RP, Adams G, Brown G, Hawthorne T *et al*. A Comparison of the efficacy and adverse effects of double-lumen endobronchial tubes and bronchial blockers in thoracic surgery: a systematic review and meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth 2015;29:955–66.
[153] de Bellis M, Accardo R, Di Maio M, La Manna C, Lamanna C, Rossi GB *et al*. Is flexible bronchoscopy necessary to confirm the position of double-lumen tubes before thoracic surgery. Eur J Cardiothorac Surg 2011;40:912–16.
[154] Klein U, Karzai W, Bloos F, Wohlfarth M, Gottschall R, Fritz H *et al*. Role of fiberoptic bronchoscopy in conjunction with the use of double-lumen tubes for thoracic anesthesia: a prospective study. Anesthesiology 1998;88:346–50.
[155] Ko R, McRae K, Darling G, Waddell TK, McGlade D, Cheung K *et al*. The use of air in the inspired gas mixture during two-lung ventilation delays lung collapse during one-lung ventilation. Anesth Analg 2009;108: 1092–6.
[156] Lohser J, Slinger P. Lung injury after one-lung ventilation: a review of the pathophysiologic mechanisms affecting the ventilated and the collapsed lung. Anesth Analg 2015;121:302–18.
[157] Brassard CL, Lohser J, Donati F, Bussières JS. Step-by-step clinical management of one-lung ventilation: continuing professional development. Can J Anaesth 2014;61:1103–21.
[158] Blank RS, Colquhoun DA, Durieux ME, Kozower BD, McMurry TL, Bender SP *et al*. Management of one-lung ventilation: impact of tidal volume on complications after thoracic surgery. Anesthesiology 2016; 124:1286–95.
[159] Végh T, Juhász M, Szatmári S, Enyedi A, Sessler DI, Szegedi LL *et al*. Effects of different tidal volumes for one-lung ventilation on oxygenation with open chest condition and surgical manipulation: a randomised cross-over trial. Minerva Anestesiol 2013;79:24–32.
[160] Ferrando C, Mugarra A, Gutierrez A, Carbonell JA, García M, Soro M *et al*. Setting individualized positive end-expiratory pressure level with a positive end-expiratory pressure decrement trial after a recruitment maneuver improves oxygenation and lung mechanics during one-lung ventilation. Anesth Analg 2014;118:657–65.
[161] Unzueta C, Tusman G, Suarez-Sipmann F, Böhm S, Moral V. Alveolar recruitment improves ventilation during thoracic surgery: a randomized controlled trial. Br J Anaesth 2012;108:517–24.
[162] Verhage RJ, Boone J, Rijkers GT, Cromheecke GJ, Kroese AC, Weijs TJ *et al*. Reduced local immune response with continuous positive airway pressure during one-lung ventilation for oesophagectomy. Br J Anaesth 2014;112:920–8.
[163] Kiss G, Castillo M. Nonintubated anesthesia in thoracic surgery: general issues. Ann Transl Med 2015;3:110.
[164] Tacconi F, Pompeo E. Non-intubated video-assisted thoracic surgery: where does evidence stand. J Thorac Dis 2016;8:S364–75.
[165] Liu J, Cui F, Pompeo E, Gonzalez-Rivas D, Chen H, Yin W *et al*. The impact of non-intubated versus intubated anaesthesia on early outcomes of video-assisted thoracoscopic anatomical resection in non-small-cell lung cancer: a propensity score matching analysis. Eur J Cardiothorac Surg 2016;50:920–5.
[166] Liu J, Cui F, Li S, Chen H, Shao W, Liang L *et al*. Nonintubated video-assisted thoracoscopic surgery under epidural anesthesia compared with conventional anesthetic option. Surg Innov 2015;22:123–30.
[167] Lumb AB, Slinger P. Hypoxic pulmonary vasoconstriction: physiology and anesthetic implications. Anesthesiology 2015;122:932–46.
[168] Schilling T, Kozian A, Kretzschmar M, Huth C, Welte T, Bühling F *et al*. Effects of propofol and desflurane anaesthesia on the alveolar inflammatory response to one-lung ventilation. Br J Anaesth 2007;99:368–75.
[169] De Conno E, Steurer MP, Wittlinger M, Zalunardo MP, Weder W, Schneiter D *et al*. Anesthetic-induced improvement of the inflammatory response to one-lung ventilation. Anesthesiology 2009;110:1316–26.
[170] Uhlig C, Bluth T, Schwarz K, Deckert S, Heinrich L, De Hert S *et al*. Effects of Volatile anesthetics on mortality and postoperative pulmonary and other complications in patients undergoing surgery: a systematic review and meta-analysis. Anesthesiology 2016;124:1230–45.
[171] Beck-Schimmer B, Bonvini JM, Braun J, Seeberger M, Neff TA, Risch TJ *et al*. Which anesthesia regimen is best to reduce morbidity and mortality in lung surgery? A multicenter randomized controlled trial. Anesthesiology 2016;125:313–21.
[172] Xia R, Xu J, Yin H, Wu H, Xia Z, Zhou D *et al*. Intravenous infusion of dexmedetomidine combined isoflurane inhalation reduces oxidative stress and potentiates hypoxia pulmonary vasoconstriction during one-lung ventilation in patients. Mediators Inflamm 2015;2015:238041.
[173] Apfel CC, Läärä E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology 1999;91: 693–700.
[174] Apfel CC, Heidrich FM, Jukar-Rao S, Jalota L, Hornuss C, Whelan RP *et al*. Evidence-based analysis of risk factors for postoperative nausea and vomiting. Br J Anaesth 2012;109:742–53.
[175] Apfel CC, Kranke P, Katz MH, Goepfert C, Papenfuss T, Rauch S *et al*. Volatile anaesthetics may be the main cause of early but not delayed

Downloaded from https://academic.oup.com/ejcts/article/doi/10.1093/ejcts/ezx124/5124324 by Hopital Maisonneuve-Rosemont user on 11 January 2022

postoperative vomiting: a randomized controlled trial of factorial design. Br J Anaesth 2002;88:659–68.
[176] Apfel CC, Philip BK, Cakmakkaya OS, Shilling A, Shi YY, Leslie JB *et al*. Who is at risk for postdischarge nausea and vomiting after ambulatory surgery. Anesthesiology 2012;117:475–86.
[177] Gan TJ, Diemunsch P, Habib AS, Kovac A, Kranke P, Meyer TA *et al*. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg 2014;118:85–113.
[178] Singh BN, Dahiya D, Bagaria D, Saini V, Kaman L, Kaje V *et al*. Effects of preoperative carbohydrates drinks on immediate postoperative outcome after day care laparoscopic cholecystectomy. Surg Endosc 2015; 29:3267–72.
[179] Yavuz MS, Kazancı D, Turan S, Aydınlı B, Selçuk G, Özgök A *et al*. Investigation of the effects of preoperative hydration on the postoperative nausea and vomiting. Biomed Res Int 2014;2014:302747.
[180] Apfel CC, Korttila K, Abdalla M, Kerger H, Turan A, Vedder I *et al*. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med 2004;350:2441–51.
[181] Elia N, Lysakowski C, Tramèr MR. Does multimodal analgesia with acetaminophen, nonsteroidal antiinflammatory drugs, or selective cyclooxygenase-2 inhibitors and patient-controlled analgesia morphine offer advantages over morphine alone? Meta-analyses of randomized trials. Anesthesiology 2005;103:1296–304.
[182] Frey UH, Scharmann P, Löhlein C, Peters J. P6 acustimulation effectively decreases postoperative nausea and vomiting in high-risk patients. Br J Anaesth 2009;102:620–5.
[183] Kim YH, Kim KS, Lee HJ, Shim JC, Yoon SW. The efficacy of several neuromuscular monitoring modes at the P6 acupuncture point in preventing postoperative nausea and vomiting. Anesth Analg 2011;112:819–23.
[184] DREAMS Trial Collaborators and West Midlands Research Collaborative. Dexamethasone versus standard treatment for postoperative nausea and vomiting in gastrointestinal surgery: randomised controlled trial (DREAMS Trial). BMJ 2017;357:j1455.
[185] Bjerregaard LS, Jensen PF, Bigler DR, Petersen RH, Møller-Sørensen H, Gefke K *et al*. High-dose methylprednisolone in video-assisted thoracoscopic surgery lobectomy: a randomized controlled trial. Eur J Cardiothorac Surg 2018;53:209–15.
[186] Eberhart LH, Graf J, Morin AM, Stief T, Kalder M, Lattermann R *et al*. Randomised controlled trial of the effect of oral premedication with dexamethasone on hyperglycaemic response to abdominal hysterectomy. Eur J Anaesthesiol 2011;28:195–201.
[187] Møiniche S, Kehlet H, Dahl JB. A qualitative and quantitative systematic review of preemptive analgesia for postoperative pain relief: the role of timing of analgesia. Anesthesiology 2002;96:725–41.
[188] Bong CL, Samuel M, Ng JM, Ip-Yam C. Effects of preemptive epidural analgesia on post-thoracotomy pain. J Cardiothorac Vasc Anesth 2005;19: 786–93.
[189] Cook TM, Counsell D, Wildsmith JA; Royal College of Anaesthetists Third National Audit Project. Major complications of central neuraxial block: report on the Third National Audit Project of the Royal College of Anaesthetists. Br J Anaesth 2009;102:179–90.
[190] Davies RG, Myles PS, Graham JM. A comparison of the analgesic efficacy and side-effects of paravertebral vs epidural blockade for thoracotomy–a systematic review and meta-analysis of randomized trials. Br J Anaesth 2006;96:418–26.
[191] Joshi GP, Bonnet F, Shah R, Wilkinson RC, Camu F, Fischer B *et al*. A systematic review of randomized trials evaluating regional techniques for postthoracotomy analgesia. Anesth Analg 2008;107:1026–40.
[192] Yeung JH, Gates S, Naidu BV, Wilson MJ, Gao Smith F. Paravertebral block versus thoracic epidural for patients undergoing thoracotomy. Cochrane Database Syst Rev 2016;2:CD009121.
[193] Scarfe AJ, Schuhmann-Hingel S, Duncan JK, Ma N, Atukorale YN, Cameron AL. Continuous paravertebral block for post-cardiothoracic surgery analgesia: a systematic review and meta-analysis. Eur J Cardiothorac Surg 2016;50:1010–18.
[194] Luketich JD, Land SR, Sullivan EA, Alvelo-Rivera M, Ward J, Buenaventura PO *et al*. Thoracic epidural versus intercostal nerve catheter plus patient-controlled analgesia: a randomized study. Ann Thorac Surg 2005;79:1845–9; discussion 1849.
[195] D'Andrilli A, Ibrahim M, Ciccone AM, Venuta F, De Giacomo T, Massullo D *et al*. Intrapleural intercostal nerve block associated with mini-thoracotomy improves pain control after major lung resection. Eur J Cardiothorac Surg 2006;29:790–4.
[196] Blanco R, Parras T, McDonnell JG, Prats-Galino A. Serratus plane block: a novel ultrasound-guided thoracic wall nerve block. Anaesthesia 2013;68: 1107–13.
[197] Khalil AE, Abdallah NM, Bashandy GM, Kaddah TA. Ultrasound-guided serratus anterior plane block versus thoracic epidural analgesia for thoracotomy pain. J Cardiothorac Vasc Anesth 2017;31:152–8.
[198] Khalil KG, Boutrous ML, Irani AD, Miller CC, Pawelek TR, Estrera AL *et al*. Operative intercostal nerve blocks with long-acting bupivacaine liposome for pain control after thoracotomy. Ann Thorac Surg 2015;100: 2013–18.
[199] Rice DC, Cata JP, Mena GE, Rodriguez-Restrepo A, Correa AM, Mehran RJ. Posterior intercostal nerve block with liposomal bupivacaine: an alternative to thoracic epidural analgesia. Ann Thorac Surg 2015;99: 1953–60.
[200] Humble SR, Dalton AJ, Li L. A systematic review of therapeutic interventions to reduce acute and chronic post-surgical pain after amputation, thoracotomy or mastectomy. Eur J Pain 2015;19:451–65.
[201] Khanbhai M, Yap KH, Mohamed S, Dunning J. Is cryoanalgesia effective for post-thoracotomy pain. Interact CardioVasc Thorac Surg 2014;18: 202–9.
[202] Cook TM, Riley RH. Analgesia following thoracotomy: a survey of Australian practice. Anaesth Intensive Care 1997;25:520–4.
[203] Remy C, Marret E, Bonnet F. Effects of acetaminophen on morphine side-effects and consumption after major surgery: meta-analysis of randomized controlled trials. Br J Anaesth 2005;94:505–13.
[204] Dahl V, Raeder JC. Non-opioid postoperative analgesia. Acta Anaesthesiol Scand 2000;44:1191–203.
[205] Ong CK, Seymour RA, Lirk P, Merry AF. Combining paracetamol (acetaminophen) with nonsteroidal antiinflammatory drugs: a qualitative systematic review of analgesic efficacy for acute postoperative pain. Anesth Analg 2010;110:1170–9.
[206] Keenan DJ, Cave K, Langdon L, Lea RE. Comparative trial of rectal indomethacin and cryoanalgesia for control of early postthoracotomy pain. Br Med J (Clin Res Ed) 1983;287:1335–7.
[207] Pavy T, Medley C, Murphy DF. Effect of indomethacin on pain relief after thoracotomy. Br J Anaesth 1990;65:624–7.
[208] Rhodes M, Conacher I, Morritt G, Hilton C. Nonsteroidal antiinflammatory drugs for postthoracotomy pain. A prospective controlled trial after lateral thoracotomy. J Thorac Cardiovasc Surg 1992;103:17–20.
[209] Barak M, Ziser A, Katz Y. Thoracic epidural local anesthetics are ineffective in alleviating post-thoracotomy ipsilateral shoulder pain. J Cardiothorac Vasc Anesth 2004;18:458–60.
[210] Burgess FW, Anderson DM, Colonna D, Sborov MJ, Cavanaugh DG. Ipsilateral shoulder pain following thoracic surgery. Anesthesiology 1993;78:365–8.
[211] Appadurai IR, Power I. NSAIDS in the postoperative period. Use with caution in elderly people. BMJ 1993;307:257.
[212] Gibson P, Weadington D, Winney RJ. NSAIDS in the postoperative period. Clinical experience confirms risk. BMJ 1993;307:257–8.
[213] Hunt I, Teh E, Southon R, Treasure T. Using non-steroidal anti-inflammatory drugs (NSAIDs) following pleurodesis. Interact CardioVasc Thorac Surg 2007;6:102–4.
[214] Rahman NM, Pepperell J, Rehal S, Saba T, Tang A, Ali N. Effect of opioids vs NSAIDs and larger vs smaller chest tube size on pain control and pleurodesis efficacy among patients with malignant pleural effusion: the TIME1 randomized clinical trial. JAMA 2015;314:2641–53.
[215] Michelet P, Guervilly C, Hélaine A, Avaro JP, Blayac D, Gaillat F *et al*. Adding ketamine to morphine for patient-controlled analgesia after thoracic surgery: influence on morphine consumption, respiratory function, and nocturnal desaturation. Br J Anaesth 2007;99: 396–403.
[216] Suzuki M, Haraguti S, Sugimoto K, Kikutani T, Shimada Y, Sakamoto A. Low-dose intravenous ketamine potentiates epidural analgesia after thoracotomy. Anesthesiology 2006;105:111–9.
[217] Kong VK, Irwin MG. Gabapentin: a multimodal perioperative drug. Br J Anaesth 2007;99:775–86.
[218] Mathiesen O, Møiniche S, Dahl JB. Gabapentin and postoperative pain: a qualitative and quantitative systematic review, with focus on procedure. BMC Anesthesiol 2007;7:6.
[219] Grosen K, Drewes AM, Højsgaard A, Pfeiffer-Jensen M, Hjortdal VE, Pilegaard HK. Perioperative gabapentin for the prevention of persistent pain after thoracotomy: a randomized controlled trial. Eur J Cardiothorac Surg 2014;46:76–85.

Downloaded from https://academic.oup.com/ejcts/article/55/1/91/5124324 by Hopital Maisonneuve-Rosemont user on 11 January 2022

[220] Zakkar M, Frazer S, Hunt I. Is there a role for gabapentin in preventing or treating pain following thoracic surgery. Interact CardioVasc Thorac Surg 2013;17:716–19.
[221] Huot MP, Chouinard P, Girard F, Ruel M, Lafontaine ER, Ferraro P. Gabapentin does not reduce post-thoracotomy shoulder pain: a randomized, double-blind placebo-controlled study. Can J Anesth/J Can Anesth 2008;55:337–43.
[222] Jokela RM, Ahonen JV, Tallgren MK, Marjakangas PC, Korttila KT. The effective analgesic dose of dexamethasone after laparoscopic hysterectomy. Anesth Analg 2009;109:607–15.
[223] Hval K, Kjetil H, Thagaard KS, Sem TK, Schlichting E, Ellen S *et al*. The prolonged postoperative analgesic effect when dexamethasone is added to a nonsteroidal antiinflammatory drug (rofecoxib) before breast surgery. Anesth Analg 2007;105:481–6.
[224] Kardash KJ, Sarrazin F, Tessler MJ, Velly AM. Single-dose dexamethasone reduces dynamic pain after total hip arthroplasty. Anesth Analg 2008; 106:1253–7.
[225] Iijima T, Brandstrup B, Rodhe P, Andrijauskas A, Svensen CH. The maintenance and monitoring of perioperative blood volume. Perioper Med (Lond) 2013;2:9.
[226] Navarro LH, Bloomstone JA, Auler JO, Cannesson M, Rocca GD, Gan TJ *et al*. Perioperative fluid therapy: a statement from the international Fluid Optimization Group. Perioper Med 2015;4:3.
[227] Tarbell JM. Shear stress and the endothelial transport barrier. Cardiovasc Res 2010;87:320–30.
[228] Ware LB, Fremont RD, Bastarache JA, Calfee CS, Matthay MA. Determining the aetiology of pulmonary oedema by the oedema fluid-to-plasma protein ratio. Eur Respir J 2010;35:331–7.
[229] Alam N, Park BJ, Wilton A, Seshan VE, Bains MS, Downey RJ *et al*. Incidence and risk factors for lung injury after lung cancer resection. Ann Thorac Surg 2007;84:1085–91; discussion 1091.
[230] Arslantas MK, Kara HV, Tuncer BB, Yildizeli B, Yuksel M, Bostanci K *et al*. Effect of the amount of intraoperative fluid administration on postoperative pulmonary complications following anatomic lung resections. J Thorac Cardiovasc Surg 2015;149:314–20; 321.e1.
[231] Brandstrup B, Tønnesen H, Beier-Holgersen R, Hjortsø E, Ørding H, Lindorff-Larsen K *et al*. Effects of intravenous fluid restriction on postoperative complications: comparison of two perioperative fluid regimens: a randomized assessor-blinded multicenter trial. Ann Surg 2003;238:641–8.
[232] Zeldin RA, Normandin D, Landtwing D, Peters RM. Postpneumonectomy pulmonary edema. J Thorac Cardiovasc Surg 1984;87:359–65.
[233] Kutlu CA, Williams EA, Evans TW, Pastorino U, Goldstraw P. Acute lung injury and acute respiratory distress syndrome after pulmonary resection. Ann Thorac Surg 2000;69:376–80.
[234] Evans RG, Naidu B. Does a conservative fluid management strategy in the perioperative management of lung resection patients reduce the risk of acute lung injury. Interact CardioVasc Thorac Surg 2012;15:498–504.
[235] Ahn HJ, Kim JA, Lee AR, Yang M, Jung HJ, Heo B. The risk of acute kidney injury from fluid restriction and hydroxyethyl starch in thoracic surgery. Anesth Analg 2016;122:186–93.
[236] Egal M, de Geus HR, van Bommel J, Groeneveld AB. Targeting oliguria reversal in perioperative restrictive fluid management does not influence the occurrence of renal dysfunction: a systematic review and meta-analysis. Eur J Anaesthesiol 2016;33:425–35.
[237] Matot I, Dery E, Bulgov Y, Cohen B, Paz J, Nesher N. Fluid management during video-assisted thoracoscopic surgery for lung resection: a randomized, controlled trial of effects on urinary output and postoperative renal function. J Thorac Cardiovasc Surg 2013;146:461–6.
[238] Puckett JR, Pickering JW, Palmer SC, McCall JL, Kluger MT, De Zoysa J *et al*. Low versus standard urine output targets in patients undergoing major abdominal surgery: a randomized noninferiority trial. Ann Surg 2017;265:874–81.
[239] Rollins KE, Lobo DN. Intraoperative goal-directed fluid therapy in elective major abdominal surgery: a meta-analysis of randomized controlled trials. Ann Surg 2016;263:465–76.
[240] Lee JH, Jeon Y, Bahk JH, Gil NS, Hong DM, Kim JH *et al*. Pulse pressure variation as a predictor of fluid responsiveness during one-lung ventilation for lung surgery using thoracotomy: randomised controlled study. Eur J Anaesthesiol 2011;28:39–44.
[241] Suehiro K, Okutani R. Stroke volume variation as a predictor of fluid responsiveness in patients undergoing one-lung ventilation. J Cardiothorac Vasc Anesth 2010;24:772–5.
[242] Assaad S, Popescu W, Perrino A. Fluid management in thoracic surgery. Curr Opin Anaesthesiol 2013;26:31–9.
[243] Assaad S, Kyriakides T, Tellides G, Kim AW, Perkal M, Perrino A. Extravascular lung water and tissue perfusion biomarkers after lung resection surgery under a normovolemic fluid protocol. J Cardiothorac Vasc Anesth 2015;29:977–83.
[244] Chappell D, Jacob M, Hofmann-Kiefer K, Conzen P, Rehm M. A rational approach to perioperative fluid management. Anesthesiology 2008;109: 723–40.
[245] Yates DR, Davies SJ, Milner HE, Wilson RJ. Crystalloid or colloid for goal-directed fluid therapy in colorectal surgery. Br J Anaesth 2014;112: 281–9.
[246] Gupta R, Gan TJ. Peri-operative fluid management to enhance recovery. Anaesthesia 2016;71(Suppl 1):40–5.
[247] Giambrone GP, Wu X, Gaber-Baylis LK, Bhat AU, Zabih R, Altorki NK *et al*. Incidence and implications of postoperative supraventricular tachycardia after pulmonary lobectomy. J Thorac Cardiovasc Surg 2016; 151:982–8.
[248] Onaitis M, D'Amico T, Zhao Y, O'Brien S, Harpole D. Risk factors for atrial fibrillation after lung cancer surgery: analysis of the Society of Thoracic Surgeons general thoracic surgery database. Ann Thorac Surg 2010;90: 368–74.
[249] Paul S, Altorki NK, Sheng S, Lee PC, Harpole DH, Onaitis MW *et al*. Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS database. J Thorac Cardiovasc Surg 2010;139:366–78.
[250] Paul S, Sedrakyan A, Chiu YL, Nasar A, Port JL, Lee PC *et al*. Outcomes after lobectomy using thoracoscopy vs thoracotomy: a comparative effectiveness analysis utilizing the Nationwide Inpatient Sample database. Eur J Cardiothorac Surg 2013;43:813–7.
[251] Falcoz PE, Puyraveau M, Thomas PA, Decaluwe H, Hürtgen M, Petersen RH *et al*. Video-assisted thoracoscopic surgery versus open lobectomy for primary non-small-cell lung cancer: a propensity-matched analysis of outcome from the European Society of Thoracic Surgeon database. Eur J Cardiothorac Surg 2016;49:602–9.
[252] Frendl G, Sodickson AC, Chung MK, Waldo AL, Gersh BJ, Tisdale JE *et al*. 2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. J Thorac Cardiovasc Surg 2014;148:e153–93.
[253] Kotova S, Wang M, Lothrop K, Grunkemeier G, Merry HE, Handy JR. $CHADS_2$ score predicts postoperative atrial fibrillation in patients undergoing elective pulmonary lobectomy. Ann Thorac Surg 2017;103: 1566–72.
[254] Wildgaard K, Ravn J, Kehlet H. Chronic post-thoracotomy pain: a critical review of pathogenic mechanisms and strategies for prevention. Eur J Cardiothorac Surg 2009;36:170–80.
[255] Elshiekh MA, Lo TT, Shipolini AR, McCormack DJ. Does muscle-sparing thoracotomy as opposed to posterolateral thoracotomy result in better recovery. Interact CardioVasc Thorac Surg 2013;16:60–7.
[256] Li S, Feng Z, Wu L, Huang Q, Pan S, Tang X *et al*. Analysis of 11 trials comparing muscle-sparing with posterolateral thoracotomy. Thorac Cardiovasc Surg 2014;62:344–52.
[257] Allama AM. Intercostal muscle flap for decreasing pain after thoracotomy: a prospective randomized trial. Ann Thorac Surg 2010;89:195–9.
[258] Cerfolio RJ, Bryant AS, Patel B, Bartolucci AA. Intercostal muscle flap reduces the pain of thoracotomy: a prospective randomized trial. J Thorac Cardiovasc Surg 2005;130:987–93.
[259] Cerfolio RJ, Bryant AS, Maniscalco LM. A nondivided intercostal muscle flap further reduces pain of thoracotomy: a prospective randomized trial. Ann Thorac Surg 2008;85:1901–6; discussion 1906–7.
[260] Cerfolio RJ, Price TN, Bryant AS, Sale Bass C, Bartolucci AA. Intracostal sutures decrease the pain of thoracotomy. Ann Thorac Surg 2003;76: 407–11; discussion 411.
[261] Ibrahim M, Menna C, Andreetti C, Puyo C, Maurizi G, D'Andrilli A *et al*. Does a multimodal no-compression suture technique of the intercostal space reduce chronic postthoracotomy pain? A prospective randomized study. J Thorac Oncol 2016;11:1460–8.
[262] Yan TD, Black D, Bannon PG, McCaughan BC. Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer. J Clin Oncol 2009;27:2553–62.
[263] Kirby TJ, Mack MJ, Landreneau RJ, Rice TW. Lobectomy–video-assisted thoracic surgery versus muscle-sparing thoracotomy. A randomized trial. J Thorac Cardiovasc Surg 1995;109:997–1001; discussion 1001.
[264] Bendixen M, Jørgensen OD, Kronborg C, Andersen C, Licht PB. Postoperative pain and quality of life after lobectomy via video-assisted

Downloaded from https://academic.oup.com/ejcts/article/53/1/105/5124324 by Hopital Maisonneuve-Rosemont user on 11 January 2022

thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial. Lancet Oncol 2016;17:836–44.
[265] Cao C, Manganas C, Ang SC, Peeceeyen S, Yan TD. Video-assisted thoracic surgery versus open thoracotomy for non-small cell lung cancer: a meta-analysis of propensity score-matched patients. Interact CardioVasc Thorac Surg 2013;16:244–9.
[266] Burt BM, Kosinski AS, Shrager JB, Onaitis MW, Weigel T. Thoracoscopic lobectomy is associated with acceptable morbidity and mortality in patients with predicted postoperative forced expiratory volume in 1 second or diffusing capacity for carbon monoxide less than 40% of normal. J Thorac Cardiovasc Surg 2014;148:19–28; discussion 28.
[267] Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143: e278S–313S.
[268] Craig SR, Leaver HA, Yap PL, Pugh GC, Walker WS. Acute phase responses following minimal access and conventional thoracic surgery. Eur J Cardiothorac Surg 2001;20:455–63.
[269] Petersen RP, Pham D, Burfeind WR, Hanish SI, Toloza EM, Harpole DH et al. Thoracoscopic lobectomy facilitates the delivery of chemotherapy after resection for lung cancer. Ann Thorac Surg 2007;83:1245–9; discussion 1250.
[270] Perna V, Carvajal AF, Torrecilla JA, Gigirey O. Uniportal video-assisted thoracoscopic lobectomy versus other video-assisted thoracoscopic lobectomy techniques: a randomized study. Eur J Cardiothorac Surg 2016; 50:411–15.
[271] Cao C, Manganas C, Ang SC, Yan TD. A systematic review and meta-analysis on pulmonary resections by robotic video-assisted thoracic surgery. Ann Cardiothorac Surg 2012;1:3–10.
[272] Wei S, Chen M, Chen N, Liu L. Feasibility and safety of robot-assisted thoracic surgery for lung lobectomy in patients with non-small cell lung cancer: a systematic review and meta-analysis. World J Surg Oncol 2017; 15:98.
[273] Refai M, Brunelli A, Salati M, Xiumè F, Pompili C, Sabbatini A. The impact of chest tube removal on pain and pulmonary function after pulmonary resection. Eur J Cardiothorac Surg 2012;41:820–2; discussion 823.
[274] Manzanet G, Vela A, Corell R, Morón R, Calderón R, Suelves C. A hydrodynamic study of pleural drainage systems: some practical consequences. Chest 2005;127:2211–21.
[275] Cerfolio RJ, Bass C, Katholi CR. Prospective randomized trial compares suction versus water seal for air leaks. Ann Thorac Surg 2001;71:1613–7.
[276] Marshall MB, Deeb ME, Bleier JI, Kucharczuk JC, Friedberg JS, Kaiser LR et al. Suction vs water seal after pulmonary resection: a randomized prospective study. Chest 2002;121:831–5.
[277] Gocyk W, Kużdżał J, Włodarczyk J, Grochowski Z, Gil T, Warmus J et al. Comparison of suction versus nonsuction drainage after lung resections: a prospective randomized trial. Ann Thorac Surg 2016;102:1119–24.
[278] Coughlin SM, Emmerton-Coughlin HM, Malthaner R. Management of chest tubes after pulmonary resection: a systematic review and meta-analysis. Can J Surg 2012;55:264–70.
[279] Deng B, Tan QY, Zhao YP, Wang RW, Jiang YG. Suction or non-suction to the underwater seal drains following pulmonary operation: meta-analysis of randomised controlled trials. Eur J Cardiothorac Surg 2010; 38:210–5.
[280] Gao S, Zhang Z, Aragón J, Brunelli A, Cassivi S, Chai Y et al. The Society for Translational Medicine: clinical practice guidelines for the postoperative management of chest tube for patients undergoing lobectomy. J Thorac Dis 2017;9:3255–64.
[281] Qiu T, Shen Y, Wang MZ, Wang YP, Wang D, Wang ZZ et al. External suction versus water seal after selective pulmonary resection for lung neoplasm: a systematic review. PLoS One 2013;8:e68087.
[282] Varela G, Jiménez MF, Novoa NM, Aranda JL. Postoperative chest tube management: measuring air leak using an electronic device decreases variability in the clinical practice. Eur J Cardiothorac Surg 2009;35:28–31.
[283] Brunelli A, Salati M, Refai M, Di Nunzio L, Xiumé F, Sabbatini A. Evaluation of a new chest tube removal protocol using digital air leak monitoring after lobectomy: a prospective randomised trial. Eur J Cardiothorac Surg 2010;37:56–60.
[284] Cerfolio RJ, Bryant AS. The benefits of continuous and digital air leak assessment after elective pulmonary resection: a prospective study. Ann Thorac Surg 2008;86:396–401.
[285] Pompili C, Detterbeck F, Papagiannopoulos K, Sihoe A, Vachlas K, Maxfield MW et al. Multicenter international randomized comparison of objective and subjective outcomes between electronic and traditional chest drainage systems. Ann Thorac Surg 2014;98:490–6; discussion 496.
[286] Gilbert S, McGuire AL, Maghera S, Sundaresan SR, Seely AJ, Maziak DE et al. Randomized trial of digital versus analog pleural drainage in patients with or without a pulmonary air leak after lung resection. J Thorac Cardiovasc Surg 2015;150:1243–9.
[287] Lijkendijk M, Licht PB, Neckelmann K. Electronic versus traditional chest tube drainage following lobectomy: a randomized trial. Eur J Cardiothorac Surg 2015;48:893–8; discussion 898.
[288] Miserocchi G, Beretta E, Rivolta I. Respiratory mechanics and fluid dynamics after lung resection surgery. Thorac Surg Clin 2010;20:345–57.
[289] Cerfolio RJ, Bryant AS. Results of a prospective algorithm to remove chest tubes after pulmonary resection with high output. J Thorac Cardiovasc Surg 2008;135:269–73.
[290] Bjerregaard LS, Jensen K, Petersen RH, Hansen HJ. Early chest tube removal after video-assisted thoracic surgery lobectomy with serous fluid production up to 500 ml/day. Eur J Cardiothorac Surg 2014;45:241–6.
[291] Alex J, Ansari J, Bahalkar P, Agarwala S, Rehman MU, Saleh A et al. Comparison of the immediate postoperative outcome of using the conventional two drains versus a single drain after lobectomy. Ann Thorac Surg 2003;76:1046–9.
[292] Gómez-Caro A, Roca MJ, Torres J, Cascales P, Terol E, Castañer J et al. Successful use of a single chest drain postlobectomy instead of two classical drains: a randomized study. Eur J Cardiothorac Surg 2006;29:562–6.
[293] Okur E, Baysungur V, Tezel C, Sevilgen G, Ergene G, Gokce M et al. Comparison of the single or double chest tube applications after pulmonary lobectomies. Eur J Cardiothorac Surg 2009;35:32–5; discussion 35.
[294] Kheterpal S, Tremper KK, Englesbe MJ, O'Reilly M, Shanks AM, Fetterman DM et al. Predictors of postoperative acute renal failure after noncardiac surgery in patients with previously normal renal function. Anesthesiology 2007;107:892–902.
[295] Kim KW, Lee JI, Kim JS, Lee YJ, Choi WJ, Jung H et al. Risk factors for urinary retention following minor thoracic surgery. Interact CardioVasc Thorac Surg 2015;20:486–92.
[296] Baidya DK, Khanna P, Maitra S. Analgesic efficacy and safety of thoracic paravertebral and epidural analgesia for thoracic surgery: a systematic review and meta-analysis. Interact CardioVasc Thorac Surg 2014;18: 626–35.
[297] Baldini G, Bagry H, Aprikian A, Carli F. Postoperative urinary retention: anesthetic and perioperative considerations. Anesthesiology 2009;110: 1139–57.
[298] Zaouter C, Kaneva P, Carli F. Less urinary tract infection by earlier removal of bladder catheter in surgical patients receiving thoracic epidural analgesia. Reg Anesth Pain Med 2009;34:542–8.
[299] Zaouter C, Ouattara A. How long is a transurethral catheter necessary in patients undergoing thoracotomy and receiving thoracic epidural analgesia? Literature review. J Cardiothorac Vasc Anesth 2015;29: 496–501.
[300] Allen MS, Blackmon SH, Nichols FC, Cassivi SD, Harmsen WS, Lechtenberg B et al. Optimal timing of urinary catheter removal after thoracic operations: a randomized controlled study. Ann Thorac Surg 2016;102:925–30.
[301] Hu Y, Craig SJ, Rowlingson JC, Morton SP, Thomas CJ, Persinger MB et al. Early removal of urinary catheter after surgery requiring thoracic epidural: a prospective trial. J Cardiothorac Vasc Anesth 2014;28:1302–6.
[302] BED REST, thrombosis, and embolism. Lancet 1958;1:465–6.
[303] Convertino VA. Cardiovascular consequences of bed rest: effect on maximal oxygen uptake. Med Sci Sports Exerc 1997;29:191–6.
[304] Castelino T, Fiore JF, Niculiseanu P, Landry T, Augustin B, Feldman LS. The effect of early mobilization protocols on postoperative outcomes following abdominal and thoracic surgery: a systematic review. Surgery 2016;159:991–1003.
[305] Granger CL, McDonald CF, Berney S, Chao C, Denehy L. Exercise intervention to improve exercise capacity and health related quality of life for patients with non-small cell lung cancer: a systematic review. Lung Cancer 2011;72:139–53.
[306] Smart NJ, White P, Allison AS, Ockrim JB, Kennedy RH, Francis NK. Deviation and failure of enhanced recovery after surgery following laparoscopic colorectal surgery: early prediction model. Colorectal Dis 2012;14:e727–34.
[307] Bonde P, Papachristos I, McCraith A, Kelly B, Wilson C, McGuigan JA et al. Sputum retention after lung operation: prospective, randomized trial shows superiority of prophylactic minitracheostomy in high-risk patients. Ann Thorac Surg 2002;74:196–202; discussion 202.

Downloaded from https://academic.oup.com/ejcts/article/55/1/91/5124324 by Hopital Maisonneuve-Rosemont user on 11 January 2022

[308] Issa MM, Healy DM, Maghur HA, Luke DA. Prophylactic minitracheotomy in lung resections. A randomized controlled study. J Thorac Cardiovasc Surg 1991;101:895–900.
[309] Abdelaziz M, Naidu B, Agostini P. Is prophylactic minitracheostomy beneficial in high-risk patients undergoing thoracotomy and lung resection. Interact CardioVasc Thorac Surg 2011;12:615–18.
[310] Agostini P, Calvert R, Subramanian H, Naidu B. Is incentive spirometry effective following thoracic surgery. Interact CardioVasc Thorac Surg 2008;7:297–300.
[311] Agostini P, Naidu B, Cieslik H, Steyn R, Rajesh PB, Bishay E *et al*. Effectiveness of incentive spirometry in patients following thoracotomy and lung resection including those at high risk for developing pulmonary complications. Thorax 2013;68:580–5.
[312] Carvalho CR, Paisani DM, Lunardi AC. Incentive spirometry in major surgeries: a systematic review. Rev Bras Fisioter 2011;15:343–50.
[313] Gosselink R, Schrever K, Cops P, Witvrouwen H, De Leyn P, Troosters T *et al*. Incentive spirometry does not enhance recovery after thoracic surgery. Crit Care Med 2000;28:679–83.
[314] Torres MF, Porfirio GJ, Carvalho AP, Riera R. Non-invasive positive pressure ventilation for prevention of complications after pulmonary resection in lung cancer patients. Cochrane Database Syst Rev 2015;9:CD010355.

Downloaded from https://academic.oup.com/ejcts/article/doi/10.1093/ejcts/ezx124/4124324 by Hopital Maisonneuve-Rosemont user on 11 January 2022